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ABSTRACT 
Monocytes and monocyte-derived cells are important players in the orchestration of 
inflammatory reactions in blood and peripheral tissues. However, little is known about the 
monocyte fate upon entry into human tissues, and current concepts are mainly based on 
animal models, with the addition of observational studies in humans that often do not allow 
determining causality. To provide additional understanding of the monocytes and the 
monocyte-derived cells in tissues, we developed three-dimensional (3D) co-culture models of 
epithelial tissues with monocytic cells implanted. These 3D tissue models in combination 
with clinical samples, including blood, saliva and tissue have been the platform for my thesis 
work on monocytes and monocytes-derived cells in chronic inflammatory diseases.  
In paper I, we identified increased mRNA expression of MMP12, COX2, TNF and DC-
SIGN, genes associated with inflammation and tissue remodeling, in gingival tissue from 
individuals with Periodontitis (PD). The increased production of MMP12 was confirmed at a 
protein level, and flow cytometry analysis identified CD68+CD64+CD14+ monocyte-derived 
cells as responsible for increased MMP12 production in tissue. In addition, monocyte-derived 
cells from PD gingival tissue had a relatively low surface expression of the co-inhibitory 
molecule CD200R. Similarly, using a multicellular 3D model of oral mucosa with induced 
inflammation showed increased MMP12 production and reduced CD200R surface expression 
by monocyte-derived cells. We identified CSF2 as a potent inducer of MMP12, and that 
treatment of CSF2-stimulated monocyte-derived cells with a CD200 ligand reduced MMP12 
production. Thus, this study identified CD200/CD200R as a potential pathway to modulate 
aberrant inflammatory reactions in order to reduce the subsequent immunopathology and 
induce resolution of chronic inflammation.  
In a follow up study (paper II), a larger patient cohort (n=436) was investigated to assess the 
potential of MMP12, as well as the S100 proteins S100A8/A9 (calprotectin) and S100A12 as 
salivary biomarkers of PD. We found that MMP12 levels reflect destruction of periodontal 
structures, while the levels of the S100s reflect periodontal inflammation, and that smoking 
and age are important to take into consideration in future studies. The presence of other 
chronic inflammatory diseases did not influence MMP12 and S100 protein levels, however 
the presence of tumor was associated with an increase in the levels of MMP12 and S100A12.   
Paper III was a methodological study, where we further developed the 3D lung tissue model 
to establish protocols for live imaging analysis of monocytes-derived cell migratory behavior 
in inflamed tissue. Inflammation was induced by TLR ligand stimulation at the apical side of 
the lung tissue models, and the level of inflammation was evaluated by flow cytometry, gene 
expression analysis as well as cytokine secretion. An immunofluorescence live-imagine 
technique was established to study the migration of the monocyte-derived dendritic cells 
(DC) in 4D (time, x, y, z) in inflamed lung tissue models. 
In paper IV, we focused on IL-17A which is a cytokine associated with human chronic 
inflammatory diseases, and that has been linked to both PD and Langerhans cell histiocytosis 
(LCH). In LCH, DC-like cells have been described to produce IL-17A, and therefore, we 
investigated whether blood monocytes had IL-17A-producing capacity. These analyses led to 
the identification of IL-17A-producing monocytes in patients with LCH, particularly evident 
in patients with the highest disease activity. In contrast, IL-17A-producing monocytes could 
not be identified in patients with PD or healthy individuals. 
In summary, these studies have contributed to the establishment of new tools to study human 
monocytes in a tissue milieu, and identified new disease-associated mechanisms and 
pathways that can be further explored to develop new immunomodulatory treatments for 
chronic inflammatory diseases.  
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1 INTRODUCTION 
1.1 AN OVERVIEW OF THE IMMUNE SYSTEM 
The host is protected through different lines of defense, starting with physical barriers, such 
as skin and mucosal tissues. All tissue barriers are equipped with specialized mechanical 
properties, anti-microbial compounds, and inflammatory mediators to protect against 
invading pathogens. The commensal microbiota is layered on top of these surface barriers to 
compete with pathogens for nutrients and space, and is separated from the epithelium by a 
thin layer of mucus, which also acts as a barrier for pathogens. The epithelium is covering all 
surfaces of the body, and a basement membrane separates the epithelium from the underlying 
connective tissue, which is vascularized and composed of a wide variety of cells including the 
white blood cells (leukocytes, immune cells). The immune cells belong either to the innate or 
the adaptive immune system, and both are present within tissues where they communicate 
with each other as well as with the tissue constituent cells. Innate immune cells of both 
lymphoid and myeloid origin are located within epithelial tissues to rapidly combat 
infections, as well as maintain tissue homeostasis. This thesis focuses on myeloid 
mononuclear phagocytic cells, which function as an arm between the innate and adaptive 
immunity, as well as conductors of immune reactions within the innate immune systems. 
These cells are equipped with receptors called pattern recognition receptors, (PRR), that 
recognize different pathogen and danger associated molecular patterns (PAMPs and 
DAMPs). Upon ligation, these receptors trigger cellular activation leading to engulfment of 
extracellular material, including infectious agents, which are processed into peptides for 
presentation to T lymphocytes. In addition, activated phagocytic cells respond immediately to 
infectious assaults or injury with production of inflammatory mediators. Besides combatting 
infections, the inflammatory cells and their secreted products can cause tissue damage, and 
when there is a lack of control, this can lead to irreversible tissue destruction. 
1.1.1 The innate immune system 
The innate immune system is able to respond rapidly to infections, and include epithelial cells 
and stromal cells, such as fibroblasts, the complement system, as well as lymphoid and 
myeloid immune cells (1). Epithelial cells form a barrier with tight intercellular junctions and 
in addition they can sense infections with PRR to rapidly respond with the production of 
antimicrobial peptides as well as cytokines to activate tissue-resident immune cells (2, 3). 
Fibroblasts are the most prevalent cells within lamina propria, with functions ranging from 
extracellular matrix (ECM) production and remodeling, production of growth factors and 
inflammatory mediators to alert and recruit immune cells (4). Residing within epithelial 
barriers, myeloid cells scavenge and clear pathogens from the lumen of certain organs, such 
as the intestine and lung (5). The process by which the pathogens are engulfed is named 
phagocytosis, a process discovered by Elie Metchnikoff who was awarded the Nobel prize in 
1908 for his discoveries (6). Once the pathogen has managed to pass the epithelial barrier into 
the lamina propria, several cell types, including the myeloid immune cells, contribute to 
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mount a strong inflammatory response. Mast cells, which are also of myeloid origin, are 
located within tissues and rapidly release inflammatory mediators such as histamine, 
proteases and leukotrienes, mediating increased vascular permeability and inflammation, 
upon encounter of multicellular pathogens, but also to allergens (7). The granulocytes are 
polymorphonuclear myeloid leukocytes comprised of three different subtypes, the neutrophils 
that are important for bacterial defense, and the eosinophils and basophils that are implicated 
in parasite defense. Upon infection, the neutrophils are rapidly recruited to the infected 
tissues where they engulf bacteria and release their granules and extracellular traps to kill 
pathogens (8).  
In addition to the granulocytes, there are mononuclear phagocytic cells including monocytes, 
monocyte-derived cells, dendritic cells (DCs) and tissue-resident macrophages that are able to 
respond to different types of infections due to their broad expression of PRR such as toll like 
receptors (TLRs) and C-type lectin receptors (CLR) (9). Among monocytes, macrophages, 
and DCs there are different subsets with overlapping and distinct functions. The family of 
DCs is particularly important for their superior endocytic function and capability to process 
engulfed proteins into peptides that can be presented on human leukocyte antigen (HLA), 
also known as major histocompatibility complex (MHC) molecules, to T lymphocytes, which 
are cells of the adaptive immune system (10). The DCs are divided into conventional DCs 
(cDCs, sometimes referred to as myeloid DC) that can be further subdivided, and into the 
plasmacytoid DCs (pDCs) (11). Monocytes and macrophages also share the ability to interact 
with T cells, mostly for the purpose of potentiating killing capacity of pathogens as well as in 
the resolution of inflammatory reactions (12, 13). Besides activation by PRR sensing, the 
immune cells can also sense stress caused by a deviation in regulatory variables such as 
oxygen levels, cell and ECM composition, and level of nutrients (14). This additional 
activation mechanism is also thought to be important in the distinction between pathogens 
and the commensals, as well as to sense multicellular pathogens (15). 
As part of the innate immune system are also cells of lymphoid origin. This includes for 
example natural killer (NK)-cells that are able to recognize virus infected cells or cells that 
differ from the host cells due to lack of HLA class I expression, known as “missing-self”, and 
are important in the protection of intracellular infections and tumors (16). In addition to NK 
cells, there are three groups of invariant lymphocytes that belong to the innate immune 
system, namely NK T cells, gamma delta (γδ) T cells, and mucosa-associated invariant T 
cells (MAITs). These cells are able to recognize different bacterial products and metabolites, 
and can sense antigens presented by infected cells through different cluster of differentiation 
(CD) 1 molecules and the MHC class I-related (MR1) protein, rather than via HLA molecules 
(17). Upon stimulation, these cells produce cytokines and chemokines important to activate 
and recruit innate and adaptive immune cells to the site of infection and inflammation. More 
recently another group of innate cells, namely the innate lymphoid cells (ILCs) were 
discovered and now comprise three distinct populations that populate lymphoid organs and 
mucosal tissues (18). Among other functions the ILCs promote barrier defense functions and 
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tissue homeostasis (18, 19). In addition to the innate immune cells, there is the complement 
system that promotes activation of immune cells, removal of antigen-antibody complexes and 
dead cells, opsonization of bacteria to facilitate phagocytosis, and pore formation in the 
membrane of pathogens (20). 
To summarize, the role of the innate immune system is to form a barrier to protect us from 
invading pathogens. When the mechanical barrier is damaged, the innate immune system 
responds within minutes to hours with a broad range of weapons to clear pathogens and 
damaged cells, and to recruit and activate other immune cells. This response can if it is 
uncontrolled for too long lead to irreversible tissue destruction, which can be the case in 
chronic inflammatory diseases. In addition, innate immune cells are constantly 
communicating with the adaptive immune cells, where innate immune cells sense pathogens 
or tissue damage, and interact with adaptive immune cells to mount antigen-specific immune 
responses (15, 21). The adaptive immune cells in turn produce a second level of cytokines 
and in the case of B cells antigen-specific antibodies. These cytokines and antibodies induce 
different effector mechanism in cells such as macrophages, epithelial cells, fibroblasts and 
granulocytes, leading to potentiated immune responses (15). A well-coordinated immune 
response can destroy invading pathogens, keep tissues intact and induce processes of wound 
healing. 
1.1.2 The adaptive immune system 
In contrast to the innate immune system, the adaptive immune system is an evolutionary 
event found only in vertebrates (22). T and B cells, which are adaptive immune cells, are able 
to rearrange their gene segments upon activation after encountering antigens. A part of the 
adaptive immunity is the T-cell mediated cellular response, which requires antigen 
presentation by other cells on HLA class I or II molecules. T cells are divided into T helper 
(TH) cells, expressing CD4, and the cytotoxic T (TC) cells expressing CD8, in addition to 
CD3 that is expressed by all T cells. Activation of the T cells and rearrangement of their 
genes encoding the T cell receptor (TCR) occur in the lymphoid organs upon antigen 
presentation by professional antigen-presenting cells (APC). Antigen-specific activation 
together with additional signals (co-stimulation and cytokines) provided by the APC, induce 
T cell activation and clonal expansion, resulting in T cells with specific functions (23). 
Activated CD8+ T cells gain killing capacities and are referred to as cytotoxic T cells (TC) 
that target infected or transformed cells expressing antigens recognized as foreign (24). CD4+ 
TH cells on the other hand are activated and differentiate into different types of effector TH 
cells, specifically TH1, TH2, TH17, and the recently described TH9 and TH22 cells, as well as 
regulatory T cells (Treg) and follicular helper T cells (Tfh), all with distinct functions to control 
the immune responses and maintain tissue homeostasis, either by suppression or activation of 
inflammatory pathways (25-27). The different T cells can also become memory cells, 
including the tissue resident memory T cells (TRM) that reside in barrier tissues to rapidly 
mount a specific immune response to a certain pathogen (28).  
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The adaptive immunity also includes a humoral response, consisting of antibody-producing B 
cells. The activation of B cells takes place in secondary lymphoid organs where the naïve B 
cells encounter antigen, independent or dependent on CD4+ TH cell interactions (TCR/HLA-
II, CD40/CD40L and cytokines) (29). Activation of the naïve B cells will lead to either 
memory B-cells that are able to present antigens or into plasma cells that produce different 
types of antibodies. In secondary lymphoid tissues the activated B cells can form germinal 
centers, a process important for antibody affinity maturation, the generation of memory B 
cells as well as formation of long-lived plasma cells (29). Antibodies have broad effects on 
several parts of the immune system, e.g., by activating immune cells to release effector 
molecules, tag pathogens by a mechanism called opsonization which facilitates phagocytosis, 
neutralize toxins and microbes, and activate the complement system (30). Taken together, the 
adaptive immune response requires education and activation by specific antigens and 
cytokines to mount a powerful and specific response aimed to target certain pathogens. If the 
education fails and the adaptive immune cells recognize a self-antigen or innocuous 
environmental antigens, autoimmune or allergic diseases, respectively, can be the 
consequence. 
 
1.2 CHRONIC TISSUE INFLAMMATION 
Chronic inflammatory diseases occur worldwide, and include heterogeneous types of diseases 
in various organs. The inflammation can either be sterile or from infectious triggers, 
associated with either autoimmune diseases or chronic infectious and inflammatory diseases. 
Autoimmune diseases are linked to certain self-antigens that trigger an adaptive immune 
response, while chronic inflammatory diseases without certain antigens linked to the 
pathogenesis are more complicated. Such chronic inflammatory diseases are often 
multifactorial, with other systemic diseases, environmental factors (smoking, diet, stress, 
allergens, medication), and genetic susceptibility linked to the on-set of the diseases, and 
involve various cell types. In addition, an altered commensal microbiota is speculated to be 
an important trigger in several chronic inflammatory diseases such as Periodontitis (PD) and 
Crohn’s disease (31, 32). However, the inflamed tissues facilitate the colonization of alternate 
microbes, such as anaerobic bacteria in the case of PD, and therefore this may result from the 
disease rather than being the cause (33). Chronic inflammation can also result from T cell 
responses to innocuous antigens, resulting in allergic diseases (28). Depending on the type of 
chronic inflammation, different lymphoid and myeloid cell subsets are implicated in the 
inflammatory reactions and disease progression. Characterizing the tissue environment as 
well as the cell subsets associated to the progression of the chronic inflammatory diseases, 
can contribute to identify new potential targets for immunomodulation.      
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1.3 MONOCYTES AND MONOCYTE-DERIVED CELLS 
This thesis focuses on blood monocytes and their tissue equivalents that we refer to as 
monocyte-derived cells, and how these cells are implicated in the pathogenesis of chronic 
inflammatory diseases. I will start with introducing the blood monocytes and their 
classification and function in blood as well as the processes by which they are recruited into 
tissues. When entering the tissue, monocytes can remain as effector cells or undergo 
differentiation to become a heterogeneous population of monocyte-derived cells. The 
differentiation of monocytes in tissue varies depending on the tissue microenvironment, 
which I will describe in more detail below. I will end with a brief introduction on the tissue-
resident macrophages that originates from an embryonic precursor, but overlap functionally 
and phenotypically with the monocyte-derived cells in tissues. Over all, monocytes are 
important for the balance between immunity and tolerance in order to maintain tissue 
homeostasis, and they are able to initiate, maintain and resolve inflammatory reactions. 
Considering their diverse roles in the different stages of the inflammatory reaction, they serve 
as potential treatment targets, by modifying disease-associated functions. 
 
1.3.1 Monocytes 
1.3.1.1 Origin and classification 
Monocytes continuously derive from hematopoietic stem cells in the adult bone marrow 
trough several developmental steps called hematopoiesis (Figure 1), after which they enter 
the peripheral blood where they constitute approximately 10-15 % of the leukocytes (34-36). 
During the last decades the understanding of the monocytes have increased tremendously, 
from the theory of monocytes as a homogenous precursor for tissue macrophages (37), to the 
knowledge that they represent a heterogeneous population of cells with a broad range of 
distinct functions (11, 38, 39). Proposing that the prefix mono not properly reflect this 
heterogeneous and highly plastic cell type. Advanced flow cytometry techniques allowing 
analysis of up to 32 different markers in one sample, as well as the rapidly developing single 
cell sequencing techniques in combination with advanced humanized animal models (36, 40), 
have contributed to the discrimination of the different monocyte subsets and their functions as 
well as their developmental relationships. 
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Figure 1. Schematic illustration of adult hematopoiesis. In bone marrow the granulocyte/macrophage progenitor 
(GMP) give rice to two distinct progenitors, the macrophage/dendritic cell (DC) progenitor (MDP) and the 
common DC progenitor (CDP). The CDP further give rise to the pre-DC that is the precursor for the 
conventional DC (cDC). In addition the CDP give rice to plasmacytoid DC (pDC). The MDP further 
differentiate into the common monocyte progenitor (cMoP), which is the precursor for blood monocytes. The 
cMoP first differentiates into classical monocytes, which are the precursor for intermediate monocytes that in 
turn differentiates into the long-lived non-classical monocytes. The classical monocytes are recruited to tissues 
where they differentiate into effector cells and monocyte-derived dendritic cells (moDC) and macrophages 
(moMΦ). It is speculated that the classical and non-classical monocytes, as well as the moMΦ can replenish the 
embryonically derived tissue-resident MΦ. Illustration by Sofia Björnfot Holmström. 
 
Today three distinct subpopulations are described based on their expression of the 
lipopolysaccharide (LPS) co-receptor CD14 (41) as well as the low affinity Fc receptor 
(FcR)III, CD16 (42) (Figure 2), namely the classical CD14++CD16-, intermediate 
CD14++CD16+, and non-classical CD14-CD16+ monocytes (11, 39, 43). Recent mass 
cytometry (CyTOF) analysis suggests expanding the panel of markers including also C-C 
chemokine receptor (CCR) 2, CD11c, HLA-DR and CD36 to more precisely discriminate the 
different monocyte subsets (44). Depending on the subset specificity, monocytes express a 
broad array of various receptors for sensing of pathogens, apoptotic cells, and inflammatory 
mediators, as well as for the adhesion to endothelial cells (43, 45, 46).           
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Figure 2. Flow cytometry gating on the three human monocyte subsets based on their differential surface 
expression of CD14 and CD16. Doublets, dead cells, HLA-DR-negative cells as well as B-cells (CD14-
negative), were excluded prior to this gating.  
1.3.1.2 Classical monocytes  
The CD14++CD16-, classical monocyte subset comprises 85-95% of the monocytes in 
peripheral blood in health. Recent findings suggest that this subset is the only monocyte 
population found in the bone marrow, and is recruited to peripheral blood in a CCR2 
dependent manner (36, 47). The CD14++CD16+ monocytes only stay in circulation for one 
day until they undergo differentiation or are cleared from the circulation either by 
extravasation into tissues or by death (36, 48). The classical monocytes express a broad array 
of inflammatory chemokine receptors, e.g. CCR1, CCR2 (Figure 3), CCR5, CCR7, C-X-C 
chemokine receptor (CXCR) 1, and CXCR2, making them highly responsive to signals that 
recruit them to sites of infection or tissue injury (49). They express different PRRs, such as 
TLRs, CLRs and nucleotide-binding oligomerization domain-like receptors (NLRs) to sense 
extracellular and intracellular pathogens (45). In responds to PRR ligation, they produce 
chemokines and proinflammatory cytokines, such as C-C motif chemokine ligand (CCL) 2, 
CCL3, CCL5, interleukin (IL)-8/CXCL8, IL-10 and IL-6 (43, 49, 50).  
 
Compared to the other monocyte subsets, the classical monocytes express higher levels of 
CLEC4D, CD33, CD99, CD163, CD1d, the adhesion molecules L-selectin (CD62L) (Figure 
3) and CD11b/Mac-1, the Fc receptors CD32 and CD64, while they display lower HLA-DR, 
CD11c, and colony stimulating factor (CSF) 1 receptor (CSF1R/CD115) expression 
compared to the other subsets (36, 45, 49). Gene expression analysis revealed that 942 and 
1456 genes were differently expressed by the classical monocytes compared to the 
intermediate and non-classical monocytes, respectively, while only 256 genes differed 
between the latter two, which is in line with the results by Zawada et al. (39, 49). Among the 
highest expressed genes in the classical monocytes are the antimicrobial S100 proteins, 
S100A8 (calgranulin A or myeloid-related protein 8 (MRP-8), S100A9 (calgranulin B or 
MRP-14), and S100A12 (calgranulin C) (39, 49). 
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Figure 3. CD62L, CCR2 and CX3CR1 median fluorescense intensity (MFI) expression on the three monocyte 
subsets from five donors. Data are presented as mean ± SD, and the Friedman test with Dunn’s multiple 
comparison test was applied to analyzed statistical differences, * p <0.05, ** p <0.01, * p <0.001. 
 
Based on studies in mouse models, the classical monocytes are suggested to migrate into 
tissues under steady state conditions, as well as the subsequent migration into lymph nodes 
where they can present antigens (13, 51, 52). Besides antigen presentation the classical 
monocytes may also activate CD8+ TC cells and NK cells via production of IL-18 and IL-15 
(53). Though, the main function of classical monocytes is suggested to be as effector cells 
and contribution to the monocyte-derived cell pool in inflamed/infected tissues. In line with 
this, classical monocytes are shown to be the most efficient monocyte subset at phagocytosis 
and together with their high expression of antimicrobial peptides, this subset have an 
important role in the innate defence against microbial pathogens (39, 43).  
1.3.1.3 Intermediate monocytes 
The origin of the intermediate monocytes has been under extensive investigation, to 
determine if it is a separate developmental line or if these cells originate from other monocyte 
subsets. For several years, theories on the classical monocytes as precursors for the other 
monocyte subsets have been proposed. This concept has, however, been difficult to prove, 
but recent animal models have shown that this may indeed be the case (48).  In addition, 
newly developed techniques have enabled this to be confirmed in a human in vivo study were 
the monocytes were traced and depleted (36, 54). By monitoring the repopulation in 
circulation, it was found that a proportion of the classical monocytes, which were the once 
arriving first, are precursors of the intermediate monocytes, which in turn matures into the 
more long-lived non-classical monocytes (36, 48). Also, a mouse model showed 
differentiation of the classical monocytes into the resident monocyte subset (Ly6Clow). This 
was found to be Notch2 dependent, via notch ligand delta-like 1 (DLL1) signalling by 
endothelial cells (55). DLL1 signalling together with the transcription factor Nr4a1 have also 
been reported to be important for the survival of the resident monocyte subset (56, 57). In 
mice though, the monocytes are only composed of two distinct subsets, the Ly6Chigh 
resembling classical monocytes, and the Ly6Clow resembling the CD16-positive monocytes 
(46), and therefore it is not possible to draw definite conclusions that this is the case for both 
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the human intermediate and non-classical monocytes. The CSF1R signalling is also important 
for the generation and survival of the intermediate as well as the non-classical monocytes 
(58). In line with this, antibodies against CSF1 diminish intermediate and non-classical 
monocytes in peripheral blood in patients with rheumatoid arthritis (RA) (59). The 
intermediate monocyte subset shares phenotype and functional characteristics with both the 
classical and non-classical monocytes, though more closely related to the non-classical subset 
(49). As the intermediate monocyte subset expresses high levels of HLA-DR, CLEC10a and 
CD40, these monocytes are often referred to as “inflammatory” monocytes (49). This is 
further strengthened due to their increase in numbers and association to several chronic 
inflammatory diseases (50, 60-66).  
These monocytes express intermediate levels of the proinflammatory chemokine receptors, 
except for CCR5, which they have high expression of, and in addition they up-regulate 
CX3CR1 (Figure 3), potentially mediated via CCL2 ligation (65, 67). The CD14++CD16+ 
monocytes are thought to stay in circulation where they are able to rapidly respond to signals 
of damage or infection by the initiation of inflammation via the production of pro-
inflammatory cytokines such as tumour necrosis factor (TNF), IL-6 and IL-1β (43, 45, 50, 
68). In addition, they are able to phagocytose micro particles (45). It is suggested that this 
monocyte subset can migrate to lymph nodes to present antigens, supported by their high 
HLA-DR and CD74 expression (39, 69). Another function associated to this subset of 
monocytes is their potential involvement in angiogenesis, identified by their gene and protein 
expression of the angiopoietin receptor Tie-2, the vascular endothelial growth factor (VEGF) 
receptor 2, and endoglin (39, 70-72). 
1.3.1.4  Non-classical monocytes 
The non-classical monocytes are the most long-lived subsets, able to stay in circulation for 
around a week or longer until they undergo cell death (36). This subset acts as a guardian of 
the blood circulation by patrolling the vessel walls in a lymphocyte function-associated 
antigen (LFA)-1 dependent manner to sense damage and infections (Figure 4) (43, 56, 73, 
74). Their crawling and patrolling behaviour might mask the actual number and phenotype of 
this subset of monocytes in peripheral blood draws. Besides low CD14 expression and high 
CD16 expression, this subset also expresses high levels of CX3CR1 (figure 3), CD115, 
CD294, siglec10, CD43, SIRPα, CD11a, and CD11c (39, 45, 49). Distinct functions by this 
subset include the production of IL1 receptor antagonist (IL1Ra) in response to bacterial 
stimuli, while the sensing of nucleic acids and viral infection by intracellular TLR3, TLR7 
and TLR8 induce production of proinflammatory cytokines and type I interferons (IFN) (43, 
45). In addition, they are also able to produce cytokines such as IL-6, IL-8, and IL-10 in 
response to stimuli (43, 49). Their SIRPα expression is shared with tissue-resident 
macrophages and together with the ability of this subset to differentiate into monocyte-
derived macrophages under the stimuli from growth factors in vitro, this subsets might be a 
blood counter-part to the “wound-healing” tissue-resident macrophages that are involved in 
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the resolution of inflammation and at steady state conditions (45, 73). It is also speculated 
that the non-classical monocytes extravasates into tissue at the resolution phase of 
inflammation to support the tissue-resident macrophages in restoring damaged tissues (Figure 
4) (75).   
 
Figure 4. Schematic illustration of the patrolling of the vessel walls in a LFA-1 dependent manner by the non-
classical monocyte, as well as the mechanism by which they may be recruited to the non-inflamed tissue or in 
the resolution phase where they are assumed to assist the tissue-resident macrophages in the wound healing 
process. The recruitment and survival of the monocytes in this scenario is speculated to be CX3CR1/CX3CL1 
mediated. PSGL-1, P-seletin glycoprotein ligand-1; ICAM-1, Intercellular adhesion molecule 1; GAG, 
glycosaminoglycan; LFA-1, lymphocyte function-associated antigen 1; CX3CR1, C-X3-C motif chemokine 
receptor 1; CX3CL1/fractalkine, C-X3-C motif chemokine ligand 1. Illustrated by Mattias Svensson and Sofia 
Björnfot Holmström.  
1.3.1.5 Monocyte recruitment to tissues 
Recruitment of immune cells to the site of infection is directed via chemokines and their 
corresponding surface receptors, which production and expression is induced by infectious 
and inflammatory stimuli (76). CCR2, mainly expressed by the classical monocytes and the 
expression of its ligands on glycosaminoglycans (GAGs) on tissue and endothelial cells, is 
pivotal in the emigration of monocytes from bone marrow to blood as well as further 
recruitment into tissues (Figure 5) (47, 52, 77, 78). CCR1 and CCR5 are also suggested to be 
involved in the recruitment of monocytes to inflamed tissues (78). In addition to chemokine-
mediated recruitment, monocyte trafficking into non-lymphoid and lymphoid tissues depend 
on different adhesion molecules (79). The binding of CD62L to its ligands on endothelial 
cells is crucial for the extravasation into tissues (Figure 5) (13). Other adhesion molecules 
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such as the Very Late Antigen-4 (VLA-4) that is activated when stimuli are present, or the 
αMβ2/Mac-1 including the monocyte/macrophage marker CD11b, are also important for the 
extravasation of monocytes (Figure 5) (80, 81). Contact with the endothelium induces the up-
regulation of HLA-DR on monocytes, facilitating their ability to present antigens (13).  
 
Figure 5. Illustration of the extravasation of monocytes from circulation into inflamed tissue, where they can 
differentiate into diverse effector cells, depending on the microenvironment. The tethering is mediated via 
different selectins and their ligands. The binding of inflammatory C-C chemokine receptor (CCR) 2 to its ligand 
CCL2, presented on glycosaminoglycans (GAGs) by endothelial cells, activates very late antigen (VLA)-4. The 
activated VLA-4 and the macrophage-associated antigen (MAC)-1 bind to intercellular adhesion molecule 
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-1, which mediates arrest of the monocytes to the 
endothelium and is followed by the extravasation. CD62L, L-selectin or SELL; MADCAM-1, mucosal vascular 
adressin cell adhesion molecule 1. Illustrated by Mattias Svensson and Sofia Björnfot Holmström. 
One of the earliest events of tissue inflammation is the massive infiltration of neutrophils, but 
also the recruitment of monocytes into tissue is rapid and can occur independently of 
neutrophils (82). It has even been suggested that monocytes are required before the 
recruitment of neutrophils, and under certain specific circumstances, this can certainly be the 
case (83). Under several inflammatory and infectious conditions, or upon challenges to the 
commensal microbiota due to breaches in epithelial barrier integrity, there is an influx of 
classical monocytes (84, 85). In addition to chemokines and cytokines, matrix 
metalloproteinases (MMPs), which are a group of enzymes that degrade ECM components, 
are important for the monocyte movement within tissues (86). The end products from the 
cleaved extracellular matrix, called matrikines, can also recruit immune cells to the site of 
tissue damage (87, 88). There are also several processes to attenuate migration of monocytes 
in the resolution phase of the inflammation, such as the IL-10 production by monocyte-
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derived cells and tissue-resident macrophages, which reduces the recruitment of monocytes 
via the inhibition of CCL2 production (89). It is challenging to define the subset origin of 
monocytes entering tissue without previous labelling, since the non-classical monocyte 
markers CD16 and CX3CR1 are rapidly up regulated on monocyte-derived cells in tissue as 
well as on in vitro cultured monocytes in the presence of CSF1 (Figure 6) (90). In addition, 
markers of classical monocytes such as CCR2 can be induced on the intermediate monocyte 
by infectious stimuli, suggesting that the migratory phenotype of the monocyte subsets differ 
in steady state and inflammation. The characteristic HLA-DRhigh expression on the 
intermediate monocytes can also be induced on the classical monocytes when they adhere to 
activated endothelial cells (13).  
 
 
 
 
 
 
 
 
Figure 6. Analysis of CD16 expression on freshly isolated monocytes, as well as their expression of CD16 after 
differentiation in the oral mucosa model at day 3 (D3) or day 7 (D7) after implantation. In parallel, the 
monocytes were also cultured in the presence of the growth factor CSF1 for macrophage-like differentiation, or 
CSF2 and IL-4 for differentiation into monocyte-derived DCs. Data is representative of four donors, and is 
presented as mean ± SD. 
Taken together, the rapid recruitment of monocytes to the site of infection or injury is crucial 
for inhibiting the dissemination of infections, and is mediated via the clearance of pathogens, 
recruitment of other circulating immune cells as well as the activation of the adaptive 
immune cells. To avoid too much tissue damage, as a result of the initial influx of immune 
cells and their inflammatory reactions, control of the inflammation is important. When this 
control is insufficient, allowing the inflammation to continue, immunopathology can arise 
and as a result chronic inflammatory diseases develop. 
1.3.2 Monocyte-derived cells 
1.3.2.1 Differentiation  
Upon entering tissues the environment dictates the fate of the monocytes. In inflamed tissue, 
depending on the time after infection as well as the extent of the infectious stimuli, 
monocytes are suggested to commit to three distinct differentiation pathways (91). At the 
start of the infection when the microbial load is high, monocytes preferably acquire the role 
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as effector monocytes resembling activated tissue-resident macrophages (91). This also 
includes the inflammatory TNF-, and cytokine-inducible nitric oxide synthase (iNOS)-
producing monocyte-derived “Tip” DCs (91-93). The effector cells are effective in killing of 
pathogens and also in producing inflammatory cytokines to instruct other immune cells. In 
this acute phase, the tissue-resident macrophages can decrease in number, likely via 
necroptosis or via their migration to lymph nodes, followed by a return in the resolution 
phase, implicating the importance of the monocytes in this phase of the inflammatory 
reaction (94, 95). Though when lower concentrations of the stimuli occur, as well as in steady 
state, monocytes may stay as monocytes or differentiate into monocyte-derived DCs, both 
able to activate T-cells (13, 45, 91, 96-98). In an in vitro study it was showed that only the 
classical monocytes were able to differentiate into monocyte-derived DCs in the presence of 
CSF2 and IL-4, and none of the monocyte subsets could acquire a pDC phenotype in the 
presence of IL-3 and fms like tyrosine kinase (Flt) 3 ligand (45).  
If the monocytes arrive to the tissue at a later time-point when the infection is under control, 
the monocytes can also differentiate into monocyte-derived macrophages that facilitate 
clearance of debris and apoptotic cells as well as promote tissue repair (75, 91, 99). In the 
dermis compartment of the skin, and in the lung and gut mucosa, as well as in the spleen and 
heart, monocytes are shown to partly or completely replenish the embryonically derived 
tissue-resident macrophages (100-102). As mentioned before, it is suggested based on mouse 
models that mainly the classical monocytes extravasates into tissues, though it is speculated 
that the non-classical monocytes migrate into tissue during steady state and in the resolution 
phase of inflammation where they differentiate into macrophage-like cells. In line with this, 
several studies on inflammatory diseases observe increased number of CD16+CX3CR1+ 
monocyte infiltration (62, 63, 103). However, it is shown that the CCR2+ classical monocytes 
change their phenotype when they enter the inflamed tissue into CCR2loCX3CR1+ and 
facilitate wound healing (84, 90).  
To support the theory of monocytes as effector cells in inflammation and infections, other 
studies also suggest that monocytes can differentiate into monocyte-derived effector cells 
resembling inflammatory macrophages in inflamed tissues, while they are suggested to 
differentiate into cells resembling the steady state tissue-resident macrophages with 
remodelling functions in the resolution phase (52, 84). In vitro differentiation of monocytes in 
the presence of the macrophage growth factor CSF1 or the DC growth factors CSF2 and IL-4 
identified CD14, CD32 and CD64 as markers of undifferentiated monocytes and monocyte-
derived macrophages, on which they were somewhat increased (104-106). Tyrosine-protein 
kinase MER (MerTK) was found to be a marker specifically expressed by the monocyte-
derived macrophages, and is involved in the efferocytosis via binding to phosphatidylserine 
on apoptotic cells as well as in homeostasis (104-106). In vitro monocyte-derived 
macrophages and DCs express a wide array of MMPs that are important for their migration 
and tissue remodelling, though in the presence of stimuli the production is induced and if 
unregulated the MMPs can cause tissue damage (107, 108). Tissue inhibitors of 
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metalloproteinases (TIMPs) are natural inhibitors for the MMPs (109). In the presence of 
CSF1 and receptor activator of nuclear factor κ B (RANK) ligand as well as microbial 
products and cytokines such as TNF, the classical monocytes can also differentiate into multi-
nucleated osteoclasts, which are macrophage-like cells specialized in bone degradation (110, 
111). 
1.3.2.2 Polarization 
Monocyte-derived cells and tissue-resident macrophages are highly plastic cells, and the 
process by which they change their phenotype following environmental changes, is referred 
to as polarization. The macrophages have been classified into classically and alternatively 
activated (112, 113). Later as well as in parallel, based on in vitro stimulations with distinct 
cytokines the macrophages were described to be either M1 (LPS + IFNγ, or with CSF2) or 
M2 (IL-4) polarized, a terminology adopted from the T cell field of research with TH1 and 
TH2 immunity (114-116). Later the M2 polarisation was further divided into M2a (IL-4 or 
IL-10), M2b (IL-13) and M2c (immune complexes + LPS) (117). Markers for the different 
in vitro differentiated phenotypes have been identified, such as CD80, CD64 and CD40 for 
the M1 and CD163, CD206 (MRC1, mannose receptor C-type 1), and CD200R for the M2 
macrophages (118, 119). The CD80 and CD40 are co-stimulatory receptors involved in the 
activation of T cells. In contrast, the markers on the “M2” cells are linked to scavenging 
(CD163, CD206) and immune inhibition (CD200R) (120). The CD200/CD200R pathway is 
important in the control of inflammatory reactions and maintenance of homeostasis, and is 
a perfect example of the immune cell-tissue cross talk. The expression of OX-2 membrane 
glycoprotein (CD200) mainly by epithelial cells, mesenchymal stem cells and fibroblasts, 
provide inhibitory signals to CD200R-expressing immune cells (121-123). In addition to 
the cytokines IL-13, IL-4, and IL-10, CSF1 also have immunosuppressive functions on the 
monocyte-derived cells and macrophages (124). 
In 2014, guidelines were introduced for in vitro polarization studies and efforts have been 
made to the understanding on how a broad array of different stimulus influences 
macrophage polarization, suggesting the correlation of certain stimuli with a specific 
phenotype (104, 125). Next, the challenge is to apply this on in vivo analyses of tissue 
myeloid cells, adding the complexity of the tissue environment, where several triggers 
occur at the same time, as well as some factors being produced constitutively by stromal 
cells (126, 127). Today, the micro environmental-induced transition of function in 
monocyte-derived cells is rather considered as a spectrum, and the same cell can undertake 
different functions over time depending on the situation (128-130). The transition is 
thought to induce epigenetic changes, which can explain tolerance and the “trained 
immunity”, e.g., the fact that a second LPS stimulation not yields the same strong response 
as the former (131, 132). The knowledge that different stimuli change the phenotype and 
transcriptional as well as epigenetic programming of the monocyte-derived macrophages 
and tissue-resident macrophages identifies them as potential candidates in cell-based 
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therapies to restore homeostasis and dampen T-cell responses (133, 134). Taken together, it 
is important to assess the environment of interest in order to link a certain cellular 
phenotype and its function. When in vitro studies are conducted it is of relevance to utilize 
the proper combination of stimuli mimicking the tissue or disease of interest, which we 
have tried to adopt in our research by the use of three-dimensional (3D) tissue models of 
oral and lung mucosa, allowing the differentiation and polarization of monocytes and 
monocyte-derived cells to occur in a tissue-like environment (135-137). 
 
 
Figure 7. An illustration on the spectrum of monocyte and macrophage functions, highlighting their importance 
in tissue homeostasis and host defence. Illustration by Sofia Björnfot Holmström. 
1.3.3 Tissue-resident macrophages 
In several locations throughout the body the tissue-resident macrophages originate from an 
embryonic progenitor and self-renew in adulthood without being replenished by monocyte-
derived cells (138). To properly distinguish the different subsets of the mononuclear 
phagocytes it is of importance to understand their ontogeny (128, 139). Considering the 
shared functions and phenotypic markers between the tissue-resident macrophages and the 
adult monocyte-derived macrophages, understanding their origin might enable to track 
specific identities of the distinct subsets. To address this issue, several fate-mapping studies 
have been conducted in animal models. These studies have revealed that the tissue-resident 
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macrophages of liver, epidermis, brain, lung and kidney, namely the Kupffer cells, 
Langerhans cells, microglia, alveolar macrophages and the resident kidney macrophages, all 
develop at an embryonic stage independently from the adult hematopoietic stem cells in 
steady state conditions (48, 138, 140, 141). Another study also show that the erythro-myeloid 
progenitors (EMPs) migrate from the yolk sac into the fetal liver to become macrophage 
precursor, followed by a CX3CR1-dependent migration into fetal organs, where they 
undertake different transcriptional programs as part of the organogenesis (142). Though, 
Karjalainen and colleagues showed that it is only the brain microglia and partially the 
epidermal Langerhans cells that originate from the yolk sac precursors, while the other 
derives from fetal hematopoietic progenitors via fetal monocytes (143). In line with this, 
CX3CR1 is mainly expressed by the microglia among the different tissue-resident 
macrophages (129). There are also studies supportive of this in humans, where patients with a 
GATA-2 mutation lack monocytes, DCs and NK cells, however they have alveolar 
macrophages and Langerhans cells (144). In line with this, the Langerhans cells in the 
epidermis remain as long as 10 years after transplantations in humans (145, 146). The early 
establishment of embryonic macrophages in all organs indicates their importance in tissue 
development and homeostasis. Well in place resident macrophages in distinct tissue 
environments acquire epigenetic modifications to gain tissue-specialized functions (147).  
The survival and proliferation of the tissue-resident macrophages are dependent on the 
CSF1R signaling, however CSF1 knock out mice still retain a proportion of the microglial 
and Langerhans cells, though a second recently discovered ligand, IL-34, is suggested to be 
important for the survival of the resident macrophages in the brain and epidermis (148-150). 
There is also evidence that there is a role for CSF2 in the longevity of the resident alveolar 
and intestinal macrophages (151, 152). In the context of inflammation, infection or injury to 
the tissue, adult bone marrow-derived monocytes can enter all tissues including brain to 
become macrophages (153). In addition, the monocyte-derived cells also replenish the 
embryonically originated tissue-resident macrophages in the gut, cardiac tissue, and partly in 
the dermis (154-156). In line with this, an elegant study of the peritoneal cavity showed that 
the monocyte-derived macrophages stay at least for several months after inflammation or 
infection to support the tissue-resident macrophages in shaping the adaptive immunity (12).  
An important function of the tissue-resident macrophages besides organ development and 
inflammation is the efferocytosis of neutrophils that shifts the phenotype of the macrophages 
into an immunosuppressive phenotype, with production of IL-10 and growth factors such as 
transforming growth factor (TGF)-β, and VEGF (157). In addition, macrophages can induce 
the production of TNF-related apoptosis-inducing ligand (TRAIL) that induce neutrophil 
apoptosis followed by their subsequent up-take by macrophages, and has been suggested as a 
therapy in chronic inflammatory diseases (158). The efferocytosis is thought to be an 
important mechanism in the maintenance of tissue homeostasis (12).  
Reviewing these articles shed light on the difficulty to identify specific markers for the 
different sources of tissue macrophages when analyzing human tissue samples, though 
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CCR2, CD14 and TREM-2 might be candidate markers to identify adult monocytes and 
monocyte-derived macrophages, and the addition of MerTK could potentially separate the 
latter two (129, 156, 159, 160). The above described environment-induced transition into a 
spectrum of functions also account for the tissue-resident macrophages. Recent advances in 
the research on induced-Pluripotent-Stem-Cells (iPSCs) have discovered a way to obtain 
primitive macrophages (iMacs), which further differentiate into tissue-resident macrophages 
(161). These cells might be help-full in the understanding of the tissue-resident macrophages. 
Addressing functions of the tissue-resident macrophages under specific conditions is of 
importance to increase the understanding of their role in disease development.  
1.4 MONOCYTES IN CHRONIC INFLAMMATORY DISEASES 
In this section, I have highlighted the current knowledge on the involvement of monocytes 
and monocyte-derived cells in chronic inflammatory diseases, with particular focus on the 
commonly occurring disease Periodontitis (PD), as well as the rare disorder Langerhans cell 
histiocytosis (LCH). Even though these diseases are different they share some features such 
as the involvement of myeloid cells and bone manifestations, as well as the increased levels 
of MMPs and the cytokine IL-17A that are associated to both PD and LCH pathogenesis 
(162-164). Also, LCH can present with periodontal manifestations, linking the pathogenesis 
of these diseases (165, 166).  
1.4.1 Periodontitis 
1.4.1.1 The gingival mucosa 
The oral cavity is a part of the digestive machinery and also in close connection to the 
respiratory tract. The majority of the oral cavity barriers are covered by a non-keratinized 
squamous epithelium, called lining mucosa. Covering the alveolar bone is the masticatory 
mucosa, named gingiva, which is a stratified squamous epithelium with varying degree of 
keratinization. Keratinization is the differentiation process of the epithelial cells, starting in 
the stratum basale where the proliferation occurs, followed by a differentiation along the 
stratum spinosum and stratum granulosum (167). The outer layer of the keratinized 
epithelium is non-vital and called stratum corneum and can only be found in parts of the 
gingiva that are exposed to mastication. Other cells in the oral epithelium are the Langerhans 
cells and intraepithelial lymphocytes (IEL), which are important for the control of the barrier 
defense through communication with the epithelial cells (168, 169). A basement membrane 
separates the epithelium from the highly-vascularized lamina propria, harboring a wide array 
of immune cells (170-172). The gingival mucosa that is in contact to the tooth is divided into 
the sulcular epithelium (SE), which is not attached to but surrounds the tooth, and the thin 
permeable junctional epithelium (JE) that is the gingival attachment to the tooth or root 
(Figure 8). Both the SE and JE are non-keratinized and therefore more vulnerable to insults 
from the commensals as well as pathogens and other triggering factors. Immune cells and 
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antimicrobial factors are constantly released through the JE into the gingival cervicular fluid 
(GCF), as a part of the defense against pathogens and the control of the commensals (173).  
 
 
1.4.1.2 Periodontal diseases 
Gingivitis is a reversible inflammatory reaction towards dental plaque accumulation, 
diagnosed by bleeding on probing (BOP) (174). Gingivitis is thought to be a stable protective 
mechanism by the host to control the microbiota, and breaches in homeostasis and transition 
into the destructive disease PD only appears in a part of the population (175, 176).  
Periodontitis (PD) is a multifactorial chronic inflammatory disease initiated in the gingival 
mucosa, leading to subsequent destruction of the neighboring tooth supportive structures 
(177-179). In PD, the inflammatory reaction results in a migration of the JE along the root 
towards the apex, leading to an increased length of the SE (180, 181). The underlying process 
is probably due to protease-mediated degradation of the collagen fibers under the JE (182, 
183). The process will lead to deeper gingival pocket and a subsequent increase in the 
bacterial load. The cause of periodontitis is speculated to be a failure of the host immune cells 
to maintain homeostasis with the commensal microbiota in the gingival cervices, leading to 
subsequent host-mediated immunopathology (184, 185). A systematic review identified the 
global prevalence of severe PD to 11.2 % (186). It is speculated that the tip-over from 
gingivitis into PD occur due to a skewed microbiota, known as dysbiosis, allowing certain 
commensals to increase and become pathobionts (187, 188). Lately, an important question 
has arisen within the PD research field: “Do the bacteria select the disease or does the disease 
select the bacteria?” and the authors behind the question suggests the latter (33). The 
transition of gingivitis into PD is rather considered to be host mediated (33, 185), and can be 
due to several factors such as immunoregulatory defects, epigenetic changes, 
immunodeficiencies or systemic diseases, medication, hormonal changes, smoking, diet and 
stress, leading to aberrant inflammatory responses (189-195). The inflammatory environment 
Figure 8. Illustration of the tooth and its supportive 
structures. The epithelium lining towards the tooth is 
divided (dashed line) into the sulcular epithelium 
(SE) and the junctional epithelium (JE). The space 
between the SE and the tooth is called the gingival 
cervice, and holds the gingival cervicular fluid 
(GCF). The distance between the upper and middle 
dashed lines can be measured with a graded 
periodontal probe, and is referred to as the 
periodontal probing depth.  
Illustrated by Sofia Björnfot Holmström. 
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and the tissue degradation results in nutrition and selection for asaccharolytic gram-negative 
bacteria, which have been associated with PD pathogenesis, though they are now rather 
suggested to be opportunistic than causative (33, 196). Blocking inflammatory pathways also 
restore the dysbiosis, further strengthening the theory that the disease selects the bacteria 
(197). The change in the microbiota due to environmental changes is called the ecological 
plaque hypothesis, and so far no specific disease-causing PD pathogens have been identified, 
but rather several pathobionts that contribute to the disease progression (33). This indicates 
that it is important to shift the focus from the microbiota to the host mediated responses and 
introduce treatments that control the inflammation. In line with this, treatments targeting host 
inflammatory pathways, especially the resolution of inflammation, have been introduced with 
promising results in animal studies (197-199). There are also modulatory treatments 
introduced in human PD in conjunction to mechanical plaque control, such as the sub-
antimicrobial low dose doxycycline that inhibits MMP activity and therefore reduce the tissue 
degradation (200). Also, systemic treatment with aspirin or the cyclooxygenase-2 (COX2) 
inhibitor Celecoxib, showed promising results in the conjunctive treatment of PD (201-204).                
In order to understand the host mediated aberrant immune responses, it is important to 
characterize the cells and cellular mediators that give rise to the uncontrolled inflammatory 
reactions and tissue degradation. In addition, it is central to understand the process of tissue 
homeostasis in the gingiva. Given the mechanical injuries from mastication and oral hygiene 
routines and the continuous communication with the microbiota, it is impressive that the host 
manages to maintain barrier functions and tissue homeostasis.  In order to maintain 
homeostasis, the immune cell compartment in the gingiva needs to balance inflammatory 
reactions with mechanisms for tolerance and wound healing. The commensals are suggested 
to be involved in this process in the intestine and skin via their interplay with the epithelium 
and the immune cells, but little is known about this process in the gingival barrier (18, 205-
208). This was highlighted in an elegant review recently published by Moutsopoulos and 
Konkel (209). Though it is suggested that the oral commensals induce the production of an 
inflammatory response to protect against pathogens, while a dysbiosis of the microbiota 
results in an immune evasion mechanism (210-212). 
Interestingly, mastication is also shown to be important for tissue homeostasis via inducing 
the accumulation of TH17 cells, which produces cytokines like IL-22 that are important for 
barrier integrity (213-215). Nevertheless, the TH17 cells are also implicated in the 
pathogenesis of PD via their increased production of IL-17A that triggers inflammatory 
reactions and osteoclastogenesis (216). Moving a step backwards, the epithelial cells, 
fibroblasts and myeloid cells in the tissue are important for the initiation of the inflammatory 
reactions and produces cytokines like IL-23 that activates the T cells, innate invariant 
lymphocytes, ILCs, and the myeloid cells them selves (217). Strengthening this, IL-23 and 
IL-17A are both associated with PD, and are implicated as treatment targets in other 
destructive inflammatory diseases (218, 219). In addition to IL-23, the PD innate cellular 
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responses also include other cytokines and chemokines, as well as MMPs that together 
contribute to tissue inflammation and degradation (183, 220-222).  
The neutrophils are frequently found in the GCF in “health” and further increased in PD, 
suggesting that they are involved both in the maintenance of tissue homeostasis and in the 
escalated inflammatory reactions in PD (223). In line with this, a knock out mouse model in 
Del-1, an inhibitor of LFA-1-mediated neutrophil recruitment, resulted in aggravation of PD 
(224). In genetic disorders where the neutrophils are defect, early-onset periodontitis is often 
occurring, showing their importance in the control of the commensals as well as their 
importance in the resolution of the inflammation, where the efferocytosis of neutrophils by 
tissue-resident macrophages reprograms the macrophages into anti-inflammatory effectors 
producing IL-10 and TGF-β (225-228). Microbial stimuli can induce epigenetic changes in 
the myeloid cells that leads to a trained immunity/tolerance, rendering them less responsive to 
a second encounter, though this mechanism can also be utilized by pathobionts to escape 
killing by the host (132, 208). Epigenetic changes can also render the cells hyper-responsive, 
which is shown for the oral epithelial cells upon TLR2 stimulation (229).  
Based on studies in a peritonitis mouse model, the infiltration of monocytes in the post-
resolution phase of inflammation is also suggested to be important in the shaping of the 
adaptive immunity with an increase in suppressive Treg cells and the establishment of a 
primed homeostasis that dictates subsequent reactions (12). This may also be carried out by 
the tissue-resident macrophages at steady state conditions and in addition they migrate to 
lymph nodes to suppress the adaptive immune response in an iNOS-dependent manner (12). 
In a mouse model, ablation of the resident Langerhans cells increased the inflammatory 
driven alveolar bone loss, suggesting their importance as immune-suppressors (230, 231), 
though this needs to be further investigated in human gingival tissue. The fact that the 
gingival barrier constantly suffers from injuries, tissue repair and wound healing are 
important functions required. These functions are potentially carried out by the monocyte-
derived macrophages and the tissue-resident macrophages in the gingiva, given their ability to 
transition into a remodeling and wound healing phenotype with production of ECM 
components and growth factors (75, 208).  
In summary, the TH17 cells and neutrophils are central players in PD pathogenesis, though I 
propose to move the spotlight on the myeloid mononuclear cells. They are likely to be 
involved in all steps of the inflammatory reaction, including the initiation, progression, 
resolution and post-resolution, and therefore potential immunomodulatory targets. Though 
we need to increase our understanding on their functions in gingival tissue as well as their 
role in human PD, in order to identify potential pathways to modulate the destructive 
inflammatory reaction. 
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1.4.1.3 Monocytes in blood, and monocyte-derived and tissue-resident macrophages in 
gingival tissue in PD 
The presence of different myeloid cells in gingival tissue in health and PD, are beginning to 
be characterized, though their origin as well as their phenotypes and functional roles remain 
to be further elucidated. In common with skin, the gingiva also holds Langerhans cells (HLA-
DR+CD1a+Langerin+) in the epithelial layer (146, 148, 232-234). The resident macrophages 
in the lamina propria are speculated to consist at least partly of adult bone marrow-derived 
monocytes that differentiate into monocyte-derived macrophages, as in lamina propria of the 
intestine (84). In line with this, the monocyte chemoattractant CCL2 is expressed in gingival 
cervicular fluid that is known to reflect the gingival environment, and its levels are increased 
in PD (235, 236). The monocytes/macrophages in the lamina propria express HLA-DR as 
well as CD68, which expression is not detectable in the epithelial compartment where the 
tissue-resident Langerhans cells reside (Figure 9).  
 
Figure 9. Confocal images of gingival tissue biopsies showing nuclei staining (blue, DAPI), HLA-DR (green, 
left) and CD68 (red, right). The dashed lines mark the epithelial lining. The HLA-DR-positive cells include both 
tissue-resident intraepithelial Langerhans cells and the lamina propria macrophages (likely to be monocyte-
derived), while the CD68 staining is only detected in the lamina propria. Scale bars represent 50 µm in the left 
image and 100 µm in the right image. 
 
RNA sequencing of peripheral blood monocytes from patients with PD, has identified that 
monocytes from PD individuals are more prone to inflammatory reactions, such as apoptosis, 
cytokine production and antigen presentation (237, 238). In line with this, it is shown in vitro 
that monocytes from PD patients, as well as monocyte-derived DC, produce elevated levels 
of inflammatory cytokines such as IL-12 and IL-1β and less anti-inflammatory IL-4 and IL-
10 (239, 240). This suggests that PD monocytes are prone to induce amplified inflammatory 
reactions already in circulation. Possible explanations may be the higher incidence of 
bacteraemia, release of danger signals from inflamed gingival tissue into blood that can 
activate the monocytes, or due to an inherited altered phenotype of the monocytes in 
individuals that develop PD. In line with the former speculation, blood DCs are shown to 
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carry antigens from oral commensals in circulation (241). The total number of blood 
monocytes is elevated in individuals with PD and studies on the monocyte subset 
composition in PD reveal increased proportion of the non-classical CD14+CD16++ monocytes 
(103, 242). In another previous study, the monocytes were grouped as one population, and the 
monocytes from the PD patients had an increased percentage of cells positive for CD16, 
which correlated with lower CD14 expression, and in vitro LPS stimulation recapitulated the 
differentiation of the monocytes into CD16-positive cells (243). An increase in the CD16-
positive monocyte compartment may reflect an activation or differentiation of the monocytes, 
given their developmental relationship (36, 48). Maybe the increased systemic inflammation 
in individuals with PD also influences the production and differentiation of monocytes in the 
bone marrow, where only the classical monocyte phenotype is present at steady state (36). 
Another speculation is that the increase in proportion of the non-classical monocytes in blood 
might be due to the increased recruitment of CD14++CD16- monocytes into inflamed gingival 
tissues. The monocytes in PD induce TH17 immune responses and the classical monocytes 
from PD compared to healthy individuals are more prone to differentiate into osteoclasts 
(217, 244, 245). Notably, the increased production of IL-17A by the TH17 cells was reported 
to induce osteoclast activation, MMP production and bone degradation (162, 246). In line 
with increased osteoclastogenesis, the RANKL-osteoprotegerin system is a promising 
biomarker candidate for PD (182, 247). 
Analyses of the immune cells in gingiva have mainly focused on the composition of immune 
cells, and revealed increased number of myeloid cells in PD (171, 172, 248). Attempts have 
been made to study the phenotype, where a study identified an increase in the proportion of 
CD16-positive monocytes/macrophages in chronic PD tissue (103). In addition, histological 
analysis of control and PD gingival tissue revealed that CCR7 and iNOS were more 
frequently expressed on the macrophages in PD, than CD163 and CD206, suggesting an 
inflammatory phenotype (249). Recently, human gingival tissue from PD and control 
individuals have also started to be explored by multi-parameter flow cytometry, which is a 
step towards identifying cell subsets and linking certain functions to specific cells (170). That 
study identified a similar proportion of the myeloid mononuclear cells in PD and controls of 
the total CD45-positive cells; nevertheless the CD45-positive cells displayed a10-fold 
increase in PD gingiva (170). Another study analysing the gingival tissue with flow 
cytometry identified that the CD68+HLA-DR+ cells also expressed CD163, CD11c, TLR2 
and TLR4 (217). The macrophages are important for the maintenance of tissue homeostasis, 
as well as in inflammatory reactions (104, 129, 250). In line with this, targeting specific 
macrophage subsets has shown to be beneficial in the treatment of PD in mice models (251, 
252). Taken together, the monocytes/macrophages in the gingiva of PD display a 
proinflammatory phenotype and besides local inflammatory reactions, PD is associated with 
systemic changes in the blood monocyte compartment. The origin of the myeloid 
mononuclear cells in gingival tissue and the gingiva-specific functions of tissue-resident 
macrophages, monocyte effector cells, as well as the monocyte-derived cells need further 
investigation. To date they are mainly grouped as one macrophage population. 
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1.4.2 Langerhans cell histiocytosis 
LCH is a rare chronic inflammatory disorder, effecting either single or multiple organs with 
manifestations in bone or soft tissues, such as lung and skin, as well as periodontal tissues 
(165, 166, 253, 254). The LCH granulomas have also been associated with activation in the 
mitogen-activated protein kinase (MAPK) pathway, Ras-RAF-MEK-ERK, and partly 
associated with a mutation in the BRAFV600E gene that is involved in this pathway, suggesting 
a neoplastic etiology as well (255, 256). In line with this, the mutation has been detected in 
classical and non-classical monocyte as well as in CD1c+ blood DCs (257). Though it is not 
verified if the mutations occur due to the chronic inflammatory environment or if the 
mutation and the proliferation of LCH cells induce the inflammatory reactions seen in LCH. 
Langerin+CD1a+ cells, as well as multinucleated cells are signatures of the LCH lesion; 
therefore the resident Langerhans cells, as well as the DC has been associated with the LCH 
inflammatory reactions and granuloma formations (163, 258). It is now known that the LCH 
cells are more closely related to bone marrow-derived cells rather than the tissue-resident 
Langerhans cells, and are suggested to derive from monocytes in a Notch1-DLL1 dependent 
manner, as well as from subsets of DCs (258-260).  
Monocyte-derived DCs as well as LCH lesion cells have been shown to express the IL-17A 
receptor (IL-17RA) and to produce IL-17A, a cytokine potent of inducing granuloma 
formations and bone manifestations, via the induction of several other cytokines and MMPs 
(163, 261). Monocyte-derived DCs responded to IL-17A with the formation of 
multinucleated giant cells and the production of MMPs and tartrate-resistant acid phosphatase 
(TRAP), in a similar way as when differentiating monocytes to osteoclasts using CSF1 and 
RANKL (163). Both MMP9 and MMP12, which were produced by the multinucleated cells, 
have been detected in LCH lesions (262, 263). In LCH patients, high levels of 
proinflammatory cytokines are present already in blood, though little is known about the 
contribution from the circulating monocyte in LCH, which are lately assumed to be the 
source of the LCH cells (257). Increasing the understanding of the myeloid blood cells in 
LCH is therefore important to better understand the disease on-set and to identify new ways 
to treat LCH. In line with this, we have analyzed the blood monocytes in LCH, and identified 
them as producer of IL-17A in circulation, which is not a normal occurrence in blood 
monocytes (164). This has paved the way for a new treatment of LCH, in depleting the 
monocytes by apheresis, which reduced the pathological IL-17A levels (264). 
1.4.3 Other chronic inflammatory diseases associated with PD 
1.4.3.1 Cardiovascular disease 
The increased risk for cardiovascular disease (CVD) in individuals with PD is well accepted 
and speculated to be due to the presence of periodontal microbes in the circulation as well as 
the increased systemic inflammation and activated immune cells that is associated with PD 
(265, 266). The systemic inflammation in PD leads to altered endothelial cell functions, with 
increased activation, whereas periodontal treatment improved the endothelial function (267)
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In common with PD and other chronic inflammatory diseases, the monocyte subset 
composition is altered in CVD, with different studies showing an increase in either the 
intermediate or the non-classical monocytes (268, 269). Another study identified elevated 
numbers of the classical monocytes as predictor of cardiovascular disease (270). 
Atherosclerosis is a common chronic form of CVD that can lead to thrombosis, myocardial 
infarction and stroke if the atherosclerotic plaque is ruptured (271). Macrophages are the 
main immune cell component in the plaque and are suggested to differentiate from recruited 
blood monocytes (272). The migration of monocytes into the lesion is suggested to depend on 
CCR5, and a role for CCR2 is also suggested (273). The engulfment of cholesterol by the 
monocyte-derived macrophages leads to the formation of foamy cells, which mature and 
form the plaque (274). The monocytes and macrophages are able of producing inflammatory 
cytokines and MMPs that contribute to the thinner wall of the plaque and an increased risk of 
rupture (108). In addition the MMPs generate matrikines from degraded ECM, especially 
from elastin, that are chemotactic for monocytes, and further increase their recruitment to the 
injured vascular wall (275). It is suggested that the intermediate monocytes are involved in 
the pathogenesis of atherosclerosis, and even though there are conflicting data on the increase 
of different subsets, the intermediate monocytes are the most frequently reported subset to 
increase in the circulation of patients with CVD (276). In line with this, the intermediate 
monocytes are suggested to be a predictor of atherosclerosis and plaque rupture (64). In 
addition to chronic inflammatory disease, other factors such as age and ethnicity has also 
been shown to alter the monocyte subset composition and functions (63, 277). 
 
1.5 THREE-DIMENSIONAL TISSUE MODELS TO STUDY MONOCYTES AND 
MONOCYTE-DERIVED CELLS UNDER PHYSIOLOGICALLY RELEVANT 
CONDITIONS 
The three-dimensional (3D) modeling technique was introduced already in the end of the 
19th century (278-280) and is based on the combined culture of different tissue constituent 
cell types in an ECM-like structure, and can be expanded to include immune cells. This 
technique can be employed in studies on the tissue response to infections, or symbiotic versus 
dysbiotic microbiota, to study tissue reconstruction after wounding, toxicology and 
pharmacology, stromal-immune cell interactions, tumor development, and for tissue 
transplant engineering, just to mention some (210, 281-286). Stimulations of monocultures 
can be useful in understanding certain pathways, though the in vivo situation is far more 
complex and a single stimulus never occur. In tissue, different cells respond differently to 
each stimulus, with the production of a wide-array of different effector molecules.  
Monocytes are highly plastic cells as told, with functions ranging from pathogen defense, 
antigen presentation, release of immunomodulatory cytokines, as well as the differentiation 
into monocyte-derived cells resembling and potentially replenishing resident DCs, 
macrophages and osteoclasts in several tissues (12, 36, 45, 100, 101, 111). It is challenging to 
study the fate of the monocytes in different tissues over time in humans; therefore the 
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knowledge to date on monocyte tissue-functions is largely based on animal models. However 
several responses are species specific, and the fact that the mouse monocytes are composed of 
two subsets, compared to the three described subsets in humans, further motivate the 
development of human tissue models with monocytes. Therefore, we chose to develop 
reproducible in vitro 3D model systems of human oral and lung mucosa for the purpose of 
studying phenotypic and functional changes of monocytes and monocyte-derived cells in 
tissue inflammation. Given their wide array of important functions in the maintenance of 
tissue homeostasis as well as in the orchestration of inflammatory reactions, the monocytes 
and their derived cells are potential targets in the development of immunomodulatory 
strategies to manage or halt chronic inflammatory diseases (287).   
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2 AIMS 
 
The overall aim of this thesis was to increase the understanding on how monocytes can 
contribute to the development and progression of chronic inflammatory diseases, with the 
main focus on periodontitis (PD).  
 
Specific aims: 
• Establish methods to explore monocyte differentiation and function within inflammed 
tissues, by utlilizing and further developing our 3D tissue models  
 
• To study the gingival tissue signature in PD with regards to monocyte/macrophage 
functions, and specifically their contribution to tissue degradation  
 
• Assess potential monocyte-associated salivary biomarkers for PD  
 
• To explore the phenotype and functions of the monocytes in periperal blood in 
patients with chronic inflammatory diseases  
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3  STUDY DESIGN 
In this section of the thesis, I give an introduction to the methodologies applied to address the 
specific aims. Detailed information about the methods and materials used you can find in the 
respective manuscripts and published articles.   
3.1 ETHICAL CONSIDERATIONS 
The regional ethics committee in Stockholm, Sweden, approved the collection of gingival 
tissue samples, and the collection of blood samples from LCH patients, PD patients and 
healthy controls, as well as the use of buffy-coated blood from anonymous donors. The 
regional ethics committee in Lund, Sweden, approved the collection of saliva samples and the 
clinical examinations. All the participants gave their written informed consent prior to 
attending a study, and all the studies were in accordance with the Declaration of Helsinki.  
3.2 STUDY GROUPS AND SAMPLE COLLECTIONS 
3.2.1 Gingival tissue samples 
The collections of gingival tissue samples were performed in conjunction with planned 
surgical procedures due to periodontitis, implant surgery, or tooth extractions. In total, 
gingival tissue samples from 33 patients with periodontitis and 30 controls were collected. 
The inclusion criteria for the PD patients were ≥ 4 teeth with a probing depth of ≥ 6 mm, and 
a persistent gingival pocket ≥ 6 mm at the site of sample collection. The control patients had 
no gingival pockets > 4 mm and no history of PD (Table 1, paper I). Patients that had taken 
antibiotics or corticosteroids during the last three months prior sample collection and patients 
with HIV, hepatitis or diabetes were not included in the study. Gingival tissue samples for 
gene expression analysis were collected and stored in RNAlater for 1-3 days at 4°C, followed 
by removal of the RNAlater and storage in -80°C until RNA extractions. For western blot 
analysis, gingival tissue samples were directly placed on dry ice and stored in at least -80°C 
until protein extraction. Gingival tissues for histology analysis were collected in Histocon and 
embedded in Cryomount within 24 h and stored at -80°C. Finally, samples for flow 
cytometry analysis were collected in complete RPMI 1640 medium on ice and processed 
within 4 h of collection. Regarding the small size of the samples (3-5 mm), it was not 
possible to perform all the different analyses on each individual patient sample.  
3.2.2 Whole blood or buffy-coated blood  
Whole blood was collected in EDTA-containing vaccutainers and peripheral blood 
mononuclear cells (PBMCs) were isolated using Lymphoprep gradient centrifugation. The 
plasma was saved for protein analysis. Monocytes were isolated with negative selection using 
EasySep monocyte enrichment kit without CD16 depletion. PBMCs were stained with 
fluorochrome-conjugated antibodies and analyzed with flow cytometry. Monocytes were 
either processed directly for mRNA analysis or cultured and stimulated for subsequent 
protein and gene expression analysis. Monocytes isolated from buffy-coated blood, with the 
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same protocol as for whole blood, were subsequently used for in vitro differentiation and 
stimulations, implantations into 3D mucosa models or used for flow cytometry analysis.        
3.2.3 Saliva samples 
The concentration of MMP12 and the S100 proteins S100A8/A9 and S100A12 in saliva were 
analyzed in a previously collected cohort of samples from a total of 436 participants (288) 
(Table 1, paper II). The participants were randomly selected and invited to fill in a health 
questionnaire, to take part in an oral examination and to provide saliva samples. The 
questionnaire included questions about systemic diseases, medication, smoking and 
experiences of oral healthcare. A detailed clinical examination was performed on all 
individuals that wanted to participate in the study, and included radiographs for evaluation of 
alveolar bone level and caries lesions, registration of bleeding on probing (BOP), periodontal 
probing depths (PPD/PD), plaque index (PI), number of manifest caries lesions (MCL), and 
registration of decayed, missing and filled teeth (DMFT). The participants chewed on 
paraffin to stimulate saliva, which was collected and stored for short term at -20°C, followed 
by centrifugation, preparations of aliquots and storage at -80°C until protein analysis.  
3.2.4 In vitro culturing and differentiation of monocytes  
Isolated monocytes were cultured in complete RPMI 1640 media with the addition of 50 
ng/ml CSF1 for a total of seven days, with half of the media being replaced at day five with 
new CSF1 added, to obtain monocyte-derived macrophages. To generate monocyte-derived 
DCs, the monocytes were cultured in the presence of 25 ng/ml CSF2 and 12.5 ng/ml IL-4. 
Monocyte-derived macrophages were used for determining the MMP12-inducing 
mechanisms, and were therefore stimulated with Prostaglandin E2, TNF, LPS as well as 
CSF2. To study the role of the CD200/CD200R pathways, a CD200 Fc chimera was added to 
the cultures together with CSF2. Following stimulations supernatants were collected, 
centrifuged and subsequently analyzed for the production of MMP12 with ELISA.  
3.3 THREE-DIMENSIONAL MUCOSA MODELS  
To study monocytes and monocyte-derived cells in a tissue setting under steady state or 
inflammatory conditions, we utilized and further developed 3D tissue models of oral and lung 
mucosa (136, 289). The models were generated in 6-well cell culture inserts, by the coating 
of the membranes with a non-cellular collagen type I matrix layer, followed by a cellular 
collagen layer containing either primary gingival fibroblasts for the oral mucosa model or the 
MRC-5 lung fibroblast cell line for the lung mucosa model (Figure 10). These layers also 
contained concentrated Dulbecco’s Modified Eagle Medium (DMEM), and after 
solidification of the collagen, normal complete DMEM was added to the wells in which the 
inserts were submerged. During a period of seven days fibroblast remodeled the collagen and 
cultures contracted, as the medium was changed every second to third day. This resulted in 
the formation of a crater-like structure, on which the monocytes or monocyte-derived DC 
(CSF2 and IL-4 differentiation), were seeded, and allowed to attach for one day (Figure 10). 
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Then the TERT-2 immortalized normal oral keratinocyte line (OKF6/TERT-2) (290) or the 
normal bronchial epithelial cell line (16HBE), immortalized with SV40 large T antigen, was 
added on top of the stromal matrix layer. The models were submerged in media for another 
two to three days, followed by culturing in the air-liquid interface, which allowed 
stratification of the epithelium (Figure 10). This set-up yielded reproducible model systems 
that we could use to study and modulate the myeloid cells in a tissue context. 
                           
 
 
 
 
 
 
 
 
 
Figure 10. Oral and lung mucosa model set up. Primary gingival fibroblasts (oral) or MRC-5 lung fibroblasts are 
expanded in culture flasks, then harvested and resuspended in a collagen type I matrix that is added into cell 
culture inserts on Day 0. The cultures are submerged in medium for seven days allowing fibroblasts to remodel 
the collagen and form the extra cellular matrix. Subsequently, primary monocytes or CSF2 and IL-4 
differentiated monocyte-derived DCs (moDC) are added on top of the stromal matrix, the “lamina propria”. At 
day 8, the epithelial cells are harvested from culture flasks, seeded onto the lamina propria, and allowed to form 
a monolayer submerged in media. After two till three days the co-cultures are air-exposed, and cultured like that 
for additional days to allow epithelial cell differentiation and generation of a stratified epithelium. Inflammatory 
stimuli were either introduced at day 9 and with a refresh in conjunction to medium changes, or a single stimulus 
for the last 18-24 h of the culturing period. Illustrated by Puran Chen. 
Analyses of monocytes differentiating in the oral mucosa models were performed with flow 
cytometry, in parallel with in vitro differentiation of monocytes with CSF1 or with CSF2 and 
IL-4; to resemble macrophage-like or DC-like phenotypes of the monocyte-derived cells. To 
determine the effect of tissue inflammation on monocyte differentiation and function in 
tissue, models were repeatedly stimulated and subsequently analyzed with flow cytometry, 
and gene expression analysis. Culture supernatants were analyzed with enzyme-linked 
immunosorbent assays (ELISA) for evaluation of protein production. To study the influence 
of stimulation on monocyte migration in tissue as well as to target pathways of monocyte 
regulation, we also performed single short (18-24 hours) stimulations at the end of the 
culturing period. Using the lung mucosa models, we have established a live-imaging 
technique to track the migration and location of the monocyte-derived DCs in the lung 
mucosa model over time with confocal microscopy (paper III). A particular focus has been 
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on understanding the phenotype and tissue damaging potential of the monocyte-derived cells 
in the oral mucosa models, with a specific focus on MMP12 (paper I). 
                      
Figure 11. Schematic illustrations on the methods applied to process and analyze the mucosa models. ELISA, 
enzyme-linked immunosorbent assay; H&E, hematoxylin and eosin; IF, immunofluorescence.  
 
3.4 GENE EXPRESSION ANALYSIS 
For the gene expression analysis, RNA was extracted from the gingival tissue samples, 
mucosa models, and cells with different isolation methods. The RNA concentration was 
measured followed by a reversed transcription into complementary DNA, which was used as 
the template for multiplex real-time polymerase chain reaction (PCR) and the standard real-
time quantitative reverse transcription PCR (qRT-PCR) analyses.   
3.4.1 Multiplex real-time PCR 
To address the effect of the tissue environment on monocyte-derived cells we applied the 
multiplex assay, analyzing the expression and relation of 12 macrophage-associated genes, 
including TNF, CXCL11, PTGS2/COX2 (associated with inflammation), IL1Ra, IDO, IL10 
(immunoregulation), DC-SIGN/CD209, MRC1/CD206 (scavenging) and FN1, PDGFD, 
MMP12 and TIMP1 (remodeling). This method was used to analyze the gene expression in 
gingival tissue samples as well as in oral mucosa models, allowing us to determine the state 
of inflammation in PD, as well as to compare results from the oral mucosa model with real 
gingival tissue. With the multiplex assay, we got the copy number of each gene reflecting the 
relative abundance. Guanine nucleotide binding protein (G protein), beta polypeptide 2-like 
1 was used as a reference gene in the multiplex assays. 
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3.4.2 Real-time qRT-PCR 
This method was employed to determine the effect of different stimulations on cells as well 
as mucosa models, on single gene levels. We used the Taqman method with specific pre-
made gene expression assay, which uses double conjugated probes, including both a reporter 
dye and a quencher, and when the probe is cleaved by the Taq DNA polymerase the dye is 
unconstrained and a signal can be detected (291). The number of cycles needed to give a 
detectable amplification/signal is measured, referred to as the threshold. The relative amount 
of the gene was calculated with the comparative threshold cycle method, using the formula 2-
ΔΔ CT. Each analyzed gene was normalized to the sample expression of glyceraldehyde-3-
phosphate dehydrogenase (GADPH). 
3.5 PROTEIN ANALYSIS 
The gene expression analyses are screening tools that gives us an idea of what pathways that 
are differently regulated, though an increase in gene expression do not always relate to a 
changed protein production. Therefore, we also analyzed the production of the proteins of 
interest.  
3.5.1 Enzyme-linked immunosorbent assay, ELISA 
ELISA was applied to measure specific protein concentrations in liquids, such as cell culture 
supernatants and saliva. We used commercially available ELISA kits according to the 
manufacturers’ instructions. The ELISAs were based on the sandwich-principle where the 
samples are incubated on plates pre-coated with capture antibodies selecting for the protein of 
interest. Following incubation, a detection antibody for the protein of interest was added to 
the plates and allowed to bind during a second incubation time. Subsequently unbound 
antibodies are washed away and the plates were incubated with an enzyme-linked antibody. 
Then a substrate is added and enzymatically converted into a colored product, where the 
intensity in coloring reflects the amount of protein in the samples. A spectrophotometer was 
used to determine the concentration of the proteins by measuring the absorbance. To translate 
the absorbance to a concentration, a standard curve with known concentrations of the specific 
protein is used. Saliva is challenging to analyze due to its viscosity, and therefore we 
performed spike-recovery and dilution tests to determine the optimal dilution of the samples, 
prior to analyzing all samples.     
3.5.2 Western blot, WB 
To determine the relative protein expression within tissues or cells, we applied WB. Prior to 
the WB it is important to determine the protein concentration in the lysates, to ensure that 
equal amount of protein is loaded, and as a control we always stained the blot with an 
antibody against the house keeping protein β-actin. The intensity of the protein of interest 
was normalized to the β-actin intensity of that sample. The WB technique mainly allows the 
comparison of the samples loaded on the same blot. A benefit with WB is that you can 
identify different forms/sizes of the protein of interest.  
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3.5.3 Flow cytometry 
Multicolor flow cytometry allows the analysis of specific proteins on the surface or inside of 
individual cells. Tissue cells can also be analyzed by flow cytometry following digestions of 
tissue in collagenase and passing through a filter membrane, which gives a single cell 
suspension. The cell suspensions are labeled with antibodies that are fluorochrome-
conjugated and specifically bind to cell surface or intracellular antigens. The higher 
concentration of antigen, the more antibody-fluorochrome complexes bind, and a stronger 
intensity is detected. The principle of flow cytometry is that different lasers illuminate the 
single stream of cells and when a fluorochrome is excited it emits light at a certain 
wavelength. Different filters allow the separation of multiple fluorochrome emissions that are 
acquired by a detector and converted into digital signals. Tough the more colors used the 
greater challenge to properly compensate between the emissions. Flow cytometry also allow 
the discrimination of cells with different sizes and granularity, based on their forward or side 
scatter patterns. Flow cytometry can provide a lot of information on a single cell level and 
provides the opportunity to identify subsets of cells based on a combination of markers.  
3.5.4  Immunofluorescence analysis with confocal microscopy 
Confocal microscopy can provide information on the spatial distribution of certain cells or 
proteins within tissues, as well as their eventual co-localization. Cryopreserved tissues are 
subsequently sectioned, fixed and permeabilised, followed by staining procedures. Several 
markers can be analyzed in the same sample or section and the principle reminds of flow 
cytometry, where specific antibodies bind to the antigen of interest. Though in 
immunofluorescence (IF) analysis, signals need to be amplified, and therefore secondary 
antibodies conjugated with the fluorescent dye are used to detect the primary antibodies that 
bind the antigen of interest. We applied IF to study the location of the myeloid mononuclear 
cells in tissues, their co-localization with certain proteins of interest and the expression of 
structural proteins, where the oral mucosa models were compared with real gingival tissue. 
We also analyzed the effect of stimuli on the expression of ECM components. In addition, 
confocal microscopy enables spatial and temporal studies, referred to as live imaging 
analyses. We have set up a protocol to analyze the lung mucosa models in 4D (x, y, z and 
time) with confocal microscopy (135). The protocol used to prepare the models for the live 
imaging analysis is illustrated in Figure 1, paper III. To analyze the different cellular 
components in the live tissue, they had to be transduced with a fluorescent protein or 
incubated with a cell tracker dye prior to inclusion in the tissue models. Stimulations were 
added to the models in close proximity to the start of the imaging, to trace cellular migration 
in response to stimuli. We used a Nikon AR1 confocal laser microscope with a resonant 
scanner that allowed for high-speed imaging.  An incubator that maintains constant 
temperature and CO2 levels, to promote cell survival, surrounds the microscope.
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4 RESULTS AND DISCUSSION  
4.1 IN VITRO MODELLING OF HUMAN TISSUE INFLAMMATION 
There are several benefits with in vitro generated 3D tissue models, including the numerous 
cell-cell and cell-ECM contacts that are allowed to form as well as the possibility to study 
mechanisms of for example immune cell fate and behavior in a more biologically relevant 
milieu. The first aim of my thesis work was to establish methods to explore human monocyte 
differentiation and function within inflamed tissues. This was conducted by utilizing and 
further developing our 3D models of mucosal tissues, and by introducing advanced 
techniques to analyze the models, including gene expression analysis, multi-color flow 
cytometry and live imaging.  
4.1.1 Establishment of the oral mucosa model with primary monocytes 
To create a reproducible system, with the monocytes as a variable, we used the normal 
human oral keratinocyte cell line, OKF6/TERT-2 (289, 290), which generated a stratified 
squamous epithelium in the model setting (Figure 12). The lamina propria was generated with 
human primary gingival fibroblast. We chose to use collagen I, which is the major constituent 
of gingival mucosa, as a supporting matrix to embed the fibroblasts in. The fibroblasts 
remodeled the matrix and produced other ECM proteins necessary for tissue structure and 
function. The addition of the epithelial cells allowed the formation of a basement membrane; 
expressing proteins such as laminin-5 and fibronectin (Figure 12; Fig. 4B, paper I), while the 
production of collagen-IV require a longer culturing period (280). The stratified epithelium 
showed a similar phenotype as real gingival tissue with the expression of the tight junction 
proteins e-cadherin and claudin, as well as the intermediate filament cytokeratin 16 (Fig 4B, 
paper I).  
 
 
 
 
 
 
Figure 12. Light microscopy image of an oral mucosa model section stained with H&E. The image shows the 
formation of a stratified squamous epithelium, which is separated from the lamina propria by a more intensely 
stained basement membrane, indicated by the arrow 
In addition to the tissue constituent cells, we also implanted freshly isolated monocytes, 
which did not interfere with the structural organization of the tissue models under steady state 
conditions. The monocytes were mainly found in the lamina propria in close proximity to the 
basement membrane (Fig. 4B, paper I). Performing the work on developing an oral mucosa 
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model with monocytes, we were inspired by a previously described model based on oral 
fibroblast and keratinocytes but no immune cells (289), and our previously described lung 
tissue model with immune cells (136). To the best of our knowledge, our newly developed 
oral mucosa model with human primary monocytes is the first such 3D tissue model to be 
described. Around the same time, however, another group have developed a somewhat 
similar model with the monocytic cell line THP-1, and investigated the crosstalk between the 
tissue and a 11 bacterial-species biofilm in a perfusion chamber (292). In addition to the 
creation of 3D models, gingival explants have also been used to study tissue-resident 
Langerhans cells (234). The development of an oral mucosa model with primary monocytes, 
we believe, is a step forward in order to increase our knowledge of human monocytes and 
their phenotype and function in oral tissue. This also provides an opportunity to introduce 
monocytes that come not only from healthy individuals, but also from individuals with 
certain disease states.  
4.1.2 The influence of the oral mucosa on monocyte differentiation 
In the 3D oral mucosa model experiments, monocyte survival and differentiation was 
supported by the tissue itself rather than by the addition of exogenous growth factors. 
Monocyte differentiation was assessed by enzymatic digestion of tissue models and 
subsequent analysis by flow cytometry. This revealed that the tissue model supported 
monocytes to differentiate into macrophage-like cells, with increased expression of CD68, 
CD14 and CD163, and low expression of CD209 and CD1a (Fig. 4E and suppl. figure 2, 
paper I). This phenotype resembled that of CSF1-differentiated monocytes, rather than CSF2 
and IL-4 differentiated monocytes, which strongly up-regulated CD209 and CD1a, that are 
associated with DCs and implicated in antigen presentation (293, 294). The tissue-supported 
differentiation of monocytes into macrophage-like cell has also been shown in co-culture 
models of intestinal mucosa, alveolar epithelium and dermis (295-297). In line with the 
generation of a macrophage-like phenotype, the oral mucosa model constitutively produces 
CSF1 (Fig. 4C, paper I), which is important for the survival and differentiation of monocytes 
in tissue (58, 150). In contrast, the differentiation of monocytes into DCs might require 
additional constituents, such as endothelial cells, T cells, and microbial stimuli that trigger 
TLRs (298-300).  
In the lung mucosa model experiments (paper III), we differentiated the monocytes into DC-
like cells with CSF2 and IL-4 prior implantation, and the tissue further contributed to their 
longevity after implantation (136). Under these conditions, monocyte-derived DCs were 
found to survive up to at least 11 days in the lung model (136). The markers used to 
determine DC- and macrophage-like phenotypes were also employed in another recent study 
comparing the differentiation potential of the distinct monocyte subsets. The study showed 
that all monocyte subsets differentiated into macrophage-like cells while only the classical 
monocytes were able to obtain a DC-like phenotype and function (45). An important follow 
up study would be to sort and implant the three distinct human monocyte subsets into 
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different 3D mucosa models, to study the fate of each subset under homeostatic conditions as 
well as in an inflammatory setting.  
4.1.3 Establishment of tissue inflammation in the mucosa models 
As one of the aims with my thesis work was to dissect monocyte differentiation and functions 
in inflamed tissues, we introduced inflammation via the stimulation with microbial products, 
such as the TLR4 ligand LPS for the oral and lung mucosa models, and also the TLR2/1 
ligand Pam3CSK4 for the lung mucosa models. In the oral mucosa model, LPS stimuli were 
used alone or in combination with IFNγ, which is produced by lymphoid cells, such as NK-
cells and effector TH1 cells in response to inflammation, and potentiate macrophage effector 
functions (130). The addition of IFNγ is often used in combination with LPS, and has for 
example been used to induce an inflammatory phenotype of macrophages in a 3D tumor co-
culture model (301). To resemble the in vivo scenario, microbial stimuli were added on the 
epithelial surface of the oral and lung mucosa models.  
In the lung mucosa model, we showed that stimulation with both TLR4 and TLR2/1 ligands 
induced DC migration (Fig. 3 and 4, paper III). To track migration, we measured the length 
and speed of the cell migration, as well as the sphericity of the cells, where a prolonged 
structure reflects increased migratory behavior. The effect of TLR stimulation on lung tissue 
inflammation was confirmed by digesting the tissue models followed by flow cytometry 
analysis of monocyte-derived DC and by mRNA analysis of whole tissue extracts, as well as 
the measurement of inflammatory cytokine production in tissue culture supernatants. We 
concluded that the stimulation with LPS changed the phenotype of the monocyte-derived 
DCs, with increased expression of HLA-DR and CD86, markers of DC activation (Fig. 5D, 
paper III). Further supporting the tissue inflammation was the observed increase in mRNA 
expression of CXCL8 and IL-1β, as well as the production of TNF (Fig. 5A-B, paper III).       
Analyzing cells from digested oral mucosa models, we identified that monocyte-derived cells 
(CD45-positive) up-regulated CD14 and CD80 surface expression in LPS and IFNγ-
stimulated models, while CD200R was adversely affected, with a significant down-regulation 
in response to LPS and IFNγ (Fig. 4F, paper I). Similar patterns in surface expression of the 
co-stimulatory CD80 and the co-inhibitory CD200R molecules were observed in in vitro 
stimulations of monocytes-derived macrophage-like cells (118). In response to stimulation 
we also assessed the expression of CD163, which was expected to decrease based on 
previous in vitro studies, were CD163 has been implicated with anti-inflammatory functions 
of macrophage-like cells (119). However, we did not detect altered CD163 molecule surface 
expression on monocyte-derived macrophage-like cells from stimulated oral mucosa models 
(Figure 13). Since our model system is more complex and not as well controlled as strict 
monolayer cultures with added cytokines, we may see differences otherwise not observed. In 
addition to CD163, CD14, CD80 and CD200R, we also assessed the influence of 
inflammatory stimuli on the expression of CD16, CD209, HLA-DR, CD141/BDCA-3 and 
CD1a on the monocyte-derived cells from the oral mucosa models (Figure 13). Among all 
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these, CD1a was the only marker that was altered, with a significant down-regulation in 
response to the combination of LPS and IFNγ (Figure 13). This may be in line with the 
properties of the tissue model to support differentiation of monocytes towards macrophage-
like cells rather than DC-like cells. 
Figure 13. Flow cytometry analysis of enzymatically digested oral mucosa models after stimulations with LPS 
alone or in the combination with IFNγ, as indicated under the bars. The median fluorescence intensity (MFI) of 
each marker was analyzed on the monocyte-derived cells from four different donors. Friedman test with Dunn’s 
multiple comparison test was applied to analyzed statistical differences, *p <0.05. Bars represent mean ± SD. 
 
In addition to surface marker expression, we analyzed the gene expression of the un-
stimulated and stimulated (LPS or LPS+IFNγ) oral mucosa models with multiplex real-time 
PCR, to investigate the expression of 12 different macrophage-associated genes including 
TNF, CXCL11, PTGS2/COX2 (associated with inflammation), IL1Ra, IDO, IL10 
(immunoregulation), DC-SIGN, MRC1 (scavenging) and FN1, PDGFD, MMP12 and TIMP1 
(remodeling). We also stimulated models without monocytes implanted to determine the 
monocyte-associated effect on the gene expression of interest. Colleagues of ours previously 
employed this multiplex assay for the analysis of the cells in bronchoalveolar lavages, where 
the different genes identified distinct activation profiles that were influenced by the airway 
microbiota (302). The oral mucosa models with monocytes that were stimulated with the 
combination of LPS and IFNγ had increased gene expression of inflammatory (COX2 and 
TNF) and tissue destructive (MMP12) components, compared to the un-stimulated models 
with monocytes (Fig. 5A-C, paper I). Stimulation with LPS only, resulted in decreased 
expression of MRC1 and IL10 (Suppl. figure 3, paper I). The models without monocytes had 
nearly undetectable expression of myeloid cell markers such as DC-SIGN/CD209, 
MRC1/CD206 and IL10, and interestingly the gene expression in models without monocytes 
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did not change much after stimulation (Fig. 5A-D and suppl. figure 3, paper I). Induced 
tissue inflammation in models with monocytes was confirmed by the quantitation of MMP12 
and TNF at a protein level in culture supernatants using ELISA, and in extracted cells by the 
detection of intracellular COX2 using flow cytometry (Fig. 5E-H, paper I). We concluded 
that the genes analyzed in the multiplex assay can provide information about distinct 
activation profiles in tissue, and therefore it was also employed to reveal differences in 
gingival tissue comparing individuals with or without PD. 
 
To confirm that monocyte-derived cells are essential for the inflammatory-induced MMP12 
production in oral mucosa models (Fig. 5A and E, paper I), we digested the tissue models 
and performed cytospins and IF staining for MMP12 in combination with CD68 or vimentin. 
This analysis demonstrated that MMP12 expression was associated with CD68+ monocyte-
derived cells rather than vimentin+ fibroblasts or epithelial cells, which are negative for both 
CD68 and vimentin (Figure 14). Thus, these findings are also in line with our ex vivo analysis 
of PD tissue identifying CD68+CD64+ cells as the predominant source of MMP12 in PD 
gingival tissue (Fig. 3B, paper I).  
 
 
 
 
 
 
 
Figure 14. Immunofluorescence images on cells from digested oral mucosa models, stained for MMP12 (green) 
and to the right CD68 (red) and to the left vimentin (red). 
Using another multicellular model system researchers found that LPS stimulation resulted in 
increased production of MMP3 and MMP9 by co-cultures of macrophages and gingival 
fibroblasts (303). Although not previously proven, this may indicate that tissue-derived 
components predispose and/or induce MMP production by monocyte-derived cells and vice 
versa. For example, in a skin model, activated monocyte-derived DCs induced the production 
of MMPs by the fibroblasts, which facilitated the migration of the DCs (86). Another 
example of tissue-mediated effect on myeloid cells is the study showing the induction of 
CCL18 in DC residing in the 3D lung tissue model, compared to DCs or models alone (136). 
These are examples on how important the crosstalk between myeloid immune cells and tissue 
constituent cells might be to orchestrate tissue inflammation. To assess the effect of tissue 
inflammation on the production of CSF1, IL-34, and CSF2, which are important growth and 
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differentiation factors for monocytes, we processed tissue models for CSF1, IL34, and CSF2 
mRNA analyses. Of these three, it was above all CSF2 mRNA expression that was induced in 
oral mucosa models stimulated with LPS and IFNγ (Figure 15). Later on, we found that LPS 
on its own was sufficient to induce increased CSF2 mRNA expression in tissue models (Fig. 
5C, paper I). CSF2 is indeed considered to be an inducible growth factor associated with 
tissue inflammation and survival of myeloid cells in barrier tissues, while CSF1 and IL-34 
belong to a group of growth factors constitutively produced at different tissue sites, and that 
are important for the longevity of embryonically-derived macrophages (58, 102, 148, 304). 
However, when CSF1 is induced at sites where it is not detected during steady state, such as 
epidermis, it can contribute to tissue inflammation (305). CSF2 has been reported, at least in 
vitro, to induce an inflammatory macrophage phenotype (118, 304). Thus, stimulation of 
tissue models with TLR ligands induces tissue inflammation, with the potential to affect the 
phenotype and function of monocytes and monocyte-derived cells (paper I and III).  
                
Figure 15. Real-time qRT-PCR analysis of the mRNA expression of the growth factors CSF1, IL-34 and CSF2, 
produced by the oral mucosa models with monocytes from three different donors in response to a 24 h 
stimulation with LPS and IFNγ. Bars represent mean ± SD. 
 
Considering the importance of the microbiota in initiating the inflammatory reaction in 
gingiva, it is also important to study the cross talk between the microbiota and host cells. 
This, Bao and colleagues recently showed by stimulating tissue models with an 11 bacterial-
species biofilm. The tissue responded with production of inflammatory cytokines and was 
able to reduce the number of several of the bacterial species (292). Another alternative is to 
culture the models with saliva or dental plaque from healthy and PD individuals to study the 
influence of different microbiota and host-derived components on tissue inflammation (210). 
Yet we have not performed these types of studies, but our newly developed tissue model 
systems can enable such studies. Although there are many benefits of the developed 3D 
tissue models, of course, there are also shortcomings. This includes among other things the 
use of cell lines, which over time could be replaced by primary cells from healthy and 
diseased tissues, which better mimic a normal tissue environment. We have not yet 
developed a system for mixing different types of immune cells, such as monocyte-derived 
cells and T cells, which would allow us to study the interaction between these cells in a 
tissue like setting. It is also critical to stress that these model systems are a simplification of 
normal tissue, which have additional components, both cellular and non-cellular, such as 
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vasculature. Finally, it is important to recall that these models can be complementary to 
patient sample analyzes and experimental in vivo models. 
4.2 INFLAMMATORY SIGNATURE IN PD GINGIVA 
Secondly, we aimed to study inflammatory signatures associated with macrophage functions 
in PD gingival tissue. In order to do this, we applied the same multiplex assay as for the oral 
mucosa models, and the expressions of the 12 genes associated with distinct macrophage 
tissue functions were compared between PD and control patients. This approach was used to 
identify the activation profile as well as a screening tool to identify targets for further analysis 
and potential immunomodulatory therapies.  
4.2.1 Gene expression in PD gingiva reflect increased inflammatory and 
tissue destructive activity 
Gingival tissue from 18 patients with PD as well as from 14 controls without PD (table 1, 
study I) were analyzed with multiplex real-time PCR for the expression of TNF, CXCL11, 
COX2 (associated with inflammation), IL1Ra, IDO, IL10 (immunoregulation), DC-SIGN, 
MRC1 (scavenging), and FN1, PDGFD, MMP12 and TIMP1 (remodeling). The genes up-
regulated in gingiva from PD patients were MMP12, COX2, TNF and DC-SIGN, while 
TIMP1 and the other analyzed genes were unaltered (Fig. 5A and suppl. figure 3, paper I). 
Lately transcriptomics have been performed on gingival tissue form diseased and healthy 
sites in patients with PD (306-308). The approach to compare diseased and healthy sites in 
the same individual I think can be a good way to identify genes associated with inflammatory 
reactions in the gingiva. However, the individual gene levels might be high to start with also 
in “healthy” gingiva from individuals with PD, with the risk of masking genes associated to 
PD. In our study, we focused on a selection of genes and compared their expression in 
gingival tissue of patients with PD and controls without PD. We think that the comparison of 
gene signatures in individuals that are susceptible to PD versus individuals that do not 
develop pathological disease is advantageous to identify PD associated alterations. However, 
a drawback could be inter-individual variations, where the gene expression levels in one 
individual with disease not necessarily leads to pathology in another individual.  
Similar to our approach of comparing gingiva from PD and control individuals, RNA 
sequencing have been performed recently by another group, and identified functions related 
to inflammation and injury as the most highly up-regulated functions in PD gingiva (248). 
That study also identified another MMP, the MMP7 to be associated with PD. Additional 
MMPs have been associated with the tissue destruction in PD, and MMP8 and MMP9 are 
suggested to be potential biomarkers for PD (309, 310). Though little is known about the 
macrophage metalloelastase, MMP12, in PD affected gingival tissue. A study on juvenile 
localized aggressive PD analyzed the effect of periodontal treatment on the level of MMP12 
in GCF, and identified a decrease in levels accompanied by improved periodontal parameters 
(311). Uncontrolled MMP12 production can lead to pathological tissue degradation and the 
increased release of membrane-bound TNF (312). In line with this, gingival tissue biopsies 
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from PD patients had significantly lower tropoelastin, one of the substrates for MMP12 (Fig. 
8, paper I). MMP12 can also attack other tissue structural proteins, as was visualized in the 
oral mucosa model treated with exogenous MMP12 and where the level of fibronectin was 
reduced (87, 88, 313) (Fig. 7, paper I). In another study, the expression of MMP12 was 
shown to be induced by orthodontic treatment, and was associated with degradation of the 
basement membrane component collagen-IV in the tension zone in the periodontal ligament 
tissue (314). In addition to the direct effects on the ECM proteins, MMP12 can also activate 
other MMPs, such as MMP3 and MMP9, both implicated in the pathogenesis of PD (307, 
309, 315). An MMP12 knock out mouse model also showed reduced tissue recruitment of 
macrophages (315). The effect of MMP12 on cell migration could be due to its ability to 
degrade ECM proteins or via the ability of MMP12 to induce chemokine production by other 
cells, such as epithelial cells (316). MMP12 can also be expressed by osteoclasts and is able 
to degrade bone matrix proteins, which in turn activates the osteoclasts (317). Several MMPs 
have been associated with PD and may explain the tissue destruction observed, and our 
finding of increased MMP12 in PD gingival tissue add to the list of MMPs linked to PD (183, 
318-321) (paper I). In addition, the conditions that we and others have observed in the 
gingival tissue of PD, likely results in increased production of inflammatory cytokines that 
leads to aggravated inflammation and a subsequent loss of tooth supportive structures (322).  
4.2.2 Monocyte-derived cells in PD gingiva display increased tissue 
destructive activity 
In order to delineate the cause of increased MMP12 production in PD gingival tissue, we next 
sought to identify the cellular source. Gingival tissue from individuals with PD and controls 
were enzymatically digested and analyzed by flow cytometry. The flow cytometry analysis 
identified a CD68+CD14+CD64+ cell population to be responsible for the increased MMP12 
production in PD (Fig. 3B, paper I). Based on the expression of CD68, CD64 and CD14, we 
considered these cells to be monocyte-derived cells (52, 160, 323, 324). Another interesting 
finding we did when analyzing the CD68+CD14+CD64+ cells in PD was the reduced surface 
expression of the co-inhibitory molecule, CD200R (Fig. 3C, paper I). The down-regulation 
of CD200R was in line with the phenotype of the monocyte-derived cells in the inflamed oral 
mucosa models (Fig. 4E, paper I). Other studies on chronic inflammatory diseases have also 
identified reduced CD200R expression by monocyte-derived cells and macrophages (120, 
121, 123, 325, 326). The reduced CD200R expression has been associated with an 
inflammatory phenotype and chronic inflammation (120, 121, 123, 325, 326). Macrophage-
like cells have also been linked to gut inflammation, and suggested to originate from classical 
monocytes based on their CD14highCD16low expression and their ability to produce MMPs 
(323). Monocyte-derived cells produce several MMPs already at steady state conditions, and 
inflammatory as well as microbial stimuli further induce their MMP producing capacities 
(107, 108). The steady state production of MMPs by monocyte-derived macrophages could 
be a mechanism for homeostatic tissue remodeling. However, increased expression and 
production of MMPs is associated with immunopathology in chronic inflammatory diseases, 
and may be potential targets for intervention (200, 327). 
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4.3 UNDERSTANDING AND MODULATING MONOCYTE MMP12-PRODUCING 
CAPACITIES 
Next, we utilized our developed oral mucosa models with monocyte-derived cells as well as 
monocultures with monocyte-derived cells, to delineate inflammatory pathways and 
especially MMP12 regulation. 
4.3.1 COX2-mediated tissue inflammation and MMP production 
The 3D tissue models can be utilized to explore pathways and mechanisms to modulate the 
increased MMP production in chronic tissue inflammation. Tissue inflammation is associated 
with inducible COX2, which is expressed in response to injury, as well as inflammatory and 
microbial mediators (328). COX2 is an enzyme involved in the conversion of arachidonic 
acid into prostacyclins, thromboxanes and the prostaglandins (PG), such as PGE2, which 
exert different inflammatory and homeostatic functions (329). The induction of COX2 and 
subsequent production of PGE2 have been shown to induce the production of several MMPs, 
such as MMP2 and MMP9, though it was not known if it modifies the production of MMP12 
(330, 331). In PD, increased levels of PGE2 have been observed and a role in bone 
degradation is suggested (332, 333). To test if the COX2/PGE2 pathway controls MMP12 
production by monocyte-derived cells in a tissue setting, we utilized our established oral 
mucosa model in combination with a small-molecule COX2 inhibitor. The models were 
stimulated with LPS, which was shown to induce MMP12 production in the oral mucosa 
models (Fig. 5E and 6D, paper I). In a set of stimulated models, we also added the COX2 
specific inhibitor, SC-58125, and incubated the models for 24 h (Figure 16). The culture 
supernatants from stimulated oral mucosa models were subsequently analyzed for the 
production of PGE2 and MMP12. The production of PGE2 was robustly inhibited, 
demonstrating the efficiency of the COX2 inhibitor (Fig. 6A, paper I). In contrast to PGE2 
production, the production of MMP12 was unaffected (Fig. 6B, paper I). Therefore we 
concluded that the COX2/PGE2 pathway is not involved in the production of MMP12 by the 
oral mucosa model. Besides giving us this valuable information, this experiment also 
highlight the usefulness of the 3D mucosa models in testing targeted interventions aimed at 
modulating tissue inflammation. 
Figure 16. Illustration of the approach we 
used for the COX2-inhibition experiment. 
Oral mucosa models with monocytes 
implanted were stimulated with LPS the last 
24 h of the culturing period, in combination 
with a COX2-inhibitor treatment in the 
culture medium. The PGE2- and MMP12-
production by the oral mucosa models were 
analyzed with ELISAs. Illustrated by Puran 
Chen. 
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4.3.2 Tissue inflammation and CSF2-induced MMP12 
Although, low levels of CSF2 can promote the survival of monocyte-derived cells and tissue-
resident macrophages in certain tissues, higher levels of CSF2 is associated with tissue 
inflammation and induces inflammatory functions in these cells (151, 252, 304). Increased 
levels of CSF2 have been associated to chronic PD and we also observed increased CSF2 
expression in the stimulated oral mucosa models (Figure 15; Fig. 6C, paper I) (334). Human 
primary monocytes were cultured with CSF1, which is constitutively produced in most 
tissues including the oral mucosa model, to generate monocyte-derived macrophage-like 
cells. Subsequently, the monocyte-derived cells were treated with CSF2 for 24 h and the 
MMP12 production was assessed by ELISA. This revealed a strong induction of MMP12 
production by monocyte-derived cells (Fig. 6D, paper I). In line with our findings, CSF2 
induced the production of MMP12 by primary monocytes and the U937 monocytic cell line, 
and IL-1β and CCL2 further enhanced the production (335). Treatment of mice with a CSF2 
blocking antibody reduced the levels of MMP3, MMP9, MMP13 and MMP14, which were 
adversely induce by an injected CSF2 vector (336). In a 3D tumor model, enhanced CSF2 
expression resulted in increased expression of MMP2, MMP9, and MMP26, and an altered 
basement membrane, which was restored by CSF2 blocking antibodies (337). These finding 
suggest that CSF2 has effects beyond MMP12 by inducing several other MMPs as well. 
4.3.3 The CD200/CD200R pathway modulates MMP12 production in 
monocyte-derived cells 
The CD200 and CD200R signaling is important for the control of myeloid cells in different 
tissues (338). It has been shown that exogenous CD200 treatment up-regulates the expression 
of CD200R and down-regulate TLR4, rendering the cells less responsive to LPS stimulation 
and inhibiting the production of pro-inflammatory cytokines (339). The reduced CD200R 
expression on the monocyte-derived cells in PD and the inflammatory oral mucosa models 
(Fig. 3C and 4F, paper I), lead us to speculate that the CD200/CD200R pathway could also 
affect MMP12 production in monocyte-derived cells. We speculated that treatment with 
CD200 could potentially attenuate the CSF2-induced MMP12 production, and indeed, 
treatment of the monocyte-derived cell with a recombinant human CD200 Fc chimera protein 
lead to reduced CSF2-induced MMP12 production (Fig. 6E, paper I). The exact molecular 
mechanisms behind CD200/CD200R-mediated attenuation of MMP12 production in 
monocyte-derived cells are not known, and therefore it is only possible to speculate. The 
CD200/CD200R ligation induces phosphorylation of downstream of tyrosine kinase 2 (Dok2) 
and the recruitment of Ras GTPase activating protein (RasGAP) that in turn inactivates the 
Ras signaling pathway (340, 341). The Ras signaling pathway is upstream of both 
phosphatidylinositol 3-kinases (PI3K) and Raf, which are upstream of the MAPKs that in 
turn controls the activator protein 1 (AP-1) motif, consisting of Jun-Fos combinations (341). 
AP-1 has been shown to regulate the transcription of MMP12 in smooth muscle cells and in 
U937 monocytes (335, 342). In addition, CSF2 has been shown to activate the Ras signaling 
pathway via JAK-STAT activation (343). Therefore, we think that the CSF2 and CD200R 
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can affect the Ras signaling pathway in different ways leading to increased or decreased AP-1 
regulated MMP12 production (Figure 17). The classical monocyte subset which is the main 
monocyte subset speculated to be recruited to inflamed tissues, have the highest AP-1 gene 
expression (49). In addition, the JAK-STAT, PI3K and Ras signaling pathways are shown to 
be up-regulated in diseased gingival tissue from individuals with PD (307, 344). However, 
the expressions of CD200R have not been addressed in PD prior to this study, and just as 
little is known on AP-1. Nevertheless, a decreased CD200R expression has been associated to 
RA, which is another chronic inflammatory diseases that involves degradation of bone, and in 
line with this, the CD200/CD200R pathway can inhibit osteoclastogenesis (122, 326).  
 
 
 
Figure 17. Illustration of the results in Study I, and speculations on mechanisms in relation to: (122, 312, 339, 
340, 342, 343). RasGAP, Ras GTPase activating protein; Dok2, downstream of tyrosine kinase 2; PI3K, 
phosphatidylinositol 3-kinases; MAPKs, mitogen-activated protein kinases; AP-1, activator protein 1. 
Illustration by Sofia Björnfot Holmström and Mattias Svensson. 
 
4.4 MONOCYTE-ASSOCIATED SALIVARY BIOMARKERS 
Diagnostics of PD is today based on clinical parameters, which are useful to identify the 
active progressed disease. However, the clinical parameters are insufficient for early 
diagnosis, and to provide information about susceptibility and prediction of disease 
progression. Identifying altered immune responses with increased risk of severe 
immunopathology might help in directing the treatment of PD and other chronic 
inflammatory diseases. Saliva has recently been introduced as a diagnostic tool in dental care 
and has several benefits compared to GCF, gingival biopsies and blood samples, since it is 
non-invasive, easy and fast to collect (345). Saliva also allow for the collection of a relatively 
large sample volume and the detection of proteins that are expressed in plasma and associated 
to systemic diseases (346). However, there are some draw backs with saliva as relatively high 
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viscosity and it is less specific for periodontal diseases than GCF, and gingival tissue (346). 
Overall, however, there are more advantages than disadvantages using saliva samples and we 
chose to try to analyze the salivary levels of MMP12, the S100A8 (calgranulin A) and 
S100A9 (calgranulin B) complex, referred to as calprotectin or as MRP-8/14, and S100A12 
(calgranulin C), all associated to monocytes and monocyte-derived cells (39, 108, 335, 347-
349).  
4.4.1 Salivary MMP12, S100A8/A9, and S100A12 in PD  
In total, 436 individuals were clinically examined, asked to fill in a health questionnaire, and 
saliva samples were collected and subsequently analyzed for the levels of MMP12, 
S100A8/A9, and S100A12. The demographics of the individuals are presented in Table 1 in 
paper II, and the clinical examinations and health questionnaire are described in detail in 
Lundgren et al 2012 (288). This study allowed for determination of the influence of oral and 
systemic diseases, as well as of non-disease related covariates, such as age, sex and smoking, 
on the levels of MMP12, S100A8/A9, and S100A12. To identify the explanatory variables 
for the biomarker candidates, we applied a multivariate regression analysis. This analysis 
identified that the percentage of sites with a PPD ≥ 4 mm, age, smoking and the presence of 
tumor (self-reported) to be explanatory for the MMP12 levels, and could explain 27.6 % of 
the variance (Table 2, paper II). A decrease in MMP12 levels in saliva were found in 
smokers and with age, while increased salivary MMP12 levels were associated with 
percentage of sites with a PPD ≥ 4mm and the presence of tumor (self-reported) (Table 2, 
paper II). The decrease in MMP in smokers can possibly be explained by an altered 
monocyte and macrophage phenotype leading to decreased MMP12 production in response 
to chronic smoke exposure (350). In addition, smoking also results in decreased GCF 
production, which also could explain the reduced MMP12 levels in saliva in smokers (351).  
The only explanatory variable for S100A8/A9 was the percentage of sites with bleeding on 
probing (BOP), which accounted for 22.9 % of the variance. The levels of S100A12 were 
associated with percentage of sites with BOP and the presence of tumor (self-reported), 
which together accounted for 22.6 % of variance (Table 2, paper II). We also found that the 
levels of MMP12, S100A8/A9 and S100A12 correlated strongly with each other (Fig. 3, 
paper II). To the best of our knowledge, this study was the first to evaluate MMP12 and 
S100A12 as potential salivary biomarker candidates for PD. Nonetheless, increased levels of 
MMP12 and S100A12 in GCF have recently been associated to localized aggressive PD and 
chronic PD, respectively (311, 352). Calprotectin (S100A8/A9) was suggested to be a 
potential biomarker for PD in a recent review and has been associated to PD in former studies 
on salivary levels, however the sample sizes were rather small (353-355). In addition, 
periodontal treatment was shown to reduce the levels of calprotectin in saliva (356).            
The S100s belong to the DAMPs and can bind to TLR4 and receptor for advanced glycation 
end products (RAGE) to activate proinflammatory signaling cascades (349). The S100A8 
and S100A9 can be produced by CSF2-differentiated macrophages and have been shown to 
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induce the production of MMPs and proinflammatory cytokines (347). In addition, S100A8 
and S100A9 can induce migration of tumor cells, probably via the increased production of 
MMP2 and MMP12 (357). Calprotectin also induces the production of pro-inflammatory 
cytokines by macrophages in RA (348), and calprotectin and S100A12 have been suggested 
as biomarkers for RA (358). Increased levels of S100A8/A9 has also been linked to 
osteoarthritis (OA) in a mouse model, and resulted in increased recruitment of the Ly6Chigh 
monocytes resembling the classical monocytes in human (359). The high levels of 
S100A8/A9 in OA could be due to increased production by infiltrating classical monocytes 
and monocyte-derived cells. This is supported by the fact that human classical monocytes 
express high levels of S100A8, S100A9, and S100A12 mRNA (39, 49). 
Besides the markers analyzed by us, there are also several other markers associated with 
innate immune responses that have shown promising results as candidate biomarkers for PD, 
such as CCL2, CCL3, IL-1β, IL-6, MMP8, MMP9, CSF1, RANKL and STREM-1 (310, 320, 
353, 360-363). Considering that PD is a multifactorial complex disease, a combination of 
host-derived and microbial markers is suggested to provide accurate diagnosis, treatment and 
risk assessment (364-366). To the panel of markers mentioned, we would like to suggest 
MMP12, S100A8/A9 and S100A12, which reflect different aspects of periodontal 
inflammation, for further investigation. 
  
4.5 IL-17A EXPRESSION IN MONOCYTES 
In several chronic inflammatory diseases affecting different types of tissues, increased gene 
expression and protein levels of the cytokine IL-17A have been identified, and linked to the 
immunopathology (163, 170, 227, 261, 367-369). In line with this, therapeutic agents 
targeting IL-17A have shown potential in several chronic inflammatory diseases (218). IL-
17A can initiate inflammatory reactions, granuloma formation and osteoclast activation, 
either directly or via inducing chemokines, cytokines, and the MMPs (162, 163, 224, 246, 
261). Besides contribution to chronic tissue inflammation, IL-17A is important in the control 
of the commensal microbiota and the maintenance of barrier functions in epithelial tissues 
(206, 370). Cells of lymphoid origin, such as TH17 cells, γδ T cells, ILC3s, NK T cells, and 
lymphoid tissue inducer (LTi) cells, are mainly described as producers of IL-17A at steady 
state as well as under inflammatory conditions (170, 371). However, it has also been shown 
that cells of myeloid origin can produce IL-17A in inflamed tissues, such as the monocyte-
derived DC in LCH lesions (163, 260, 371). Though it is not known if the blood monocytes, 
which are precursors for monocyte-derived DC and potentially also for the LCH specific 
multinucleated cells, produce IL-17A already in circulation. Therefore, Study IV was 
conducted. 
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4.5.1 LCH monocytes produce IL-17A  
To study the IL-17A expression in blood monocytes, we isolated PBMCs from healthy 
controls and patients with LCH, as well as from patients with PD, and performed flow 
cytometry and RT-qPCR analyses. The flow cytometry analysis revealed that almost the 
whole fraction of LCH monocytes was producers of IL-17A, while lymphoid cells were 
negative for IL-17A. Monocytes from healthy controls or patients with PD were also negative 
for IL-17A (Figure 18; Fig. 1A and 2A-B, paper IV). In line with our findings, plasma or 
serum from LCH patients contain increased levels of IL-17A (163, 261, 372). Increased 
levels of IL-17A have also been observed in PD plasma (162, 373). The increased levels of 
IL-17A in plasma in PD could potentially reside from leakage of inflammatory mediators in 
inflamed tissues into the blood stream, or from the lymphoid compartment in blood, however, 
the number of CD4+IL-17A+ T cells was not increase in PD blood compared to controls 
(244). At the time of our study there was a controversy in the field whether the reagents used 
for the detection of IL-17A protein with ELISAs and WB specifically recognized IL-17A and 
therefore such analyzes were not performed. Later, however, plasma analyzes have been 
performed on this cohort, analyzing both cerebral spinal fluid and plasma, and there are 
indications that elevated levels of IL-17A accompany disease activity (unpublished 
observation and (264)).  
 
In addition, the analysis of IL-17A mRNA expression in PBMCs and monocytes from 
controls, LCH and PD patients revealed that the LCH monocytes had the highest IL-17A 
mRNA expression (Fig. 3A, paper IV). Since we were also interested in knowing which 
types of cells could respond to IL-17A in the circulation, we analyzed the expression of IL-
17RA on leukocytes in blood. This identified that the majority of monocytes as well as 
subpopulations of lymphocytes express the IL-17RA on the cell surface (Fig. 1, paper IV). 
In a study comparing single and multiple system LCH, increased levels of the IL-17RA was 
identified in lesions in patients with multiple system LCH (261).  
4.5.2 Mechanisms of IL-17A production by LCH monocytes   
TLR stimulation induces the production of IL-23 by monocyte-derived cells, neutrophils, and 
epithelial cells, which in turn can stimulate the production of IL-17A by cells expressing the 
IL-23R (217, 219, 244, 374). In line with this, we showed that stimulation with IL-23 or with 
phorbol myristate acetate and Ionomycin induced elevated IL-17A mRNA expression in 
monocytes (Fig. 3E, paper IV). The synthesis of IL-17A in lymphoid cells is regulated by 
Figure 18. Flow cytometry analysis of 
the intracellular IL-17A expression in 
the monocytes from a patient with PD. 
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the transcription factor RORγt (encoded by RORC) (371). To verify the existence of this 
pathway also in blood monocytes producing IL-17A, the IL-17A-positive monocytes were 
analyzed for their expression of RORγt by flow cytometry. Indeed, the LCH IL-17A+ 
monocytes expressed RORγt (Fig. 2C, paper IV), and in line with this the LCH monocyte 
mRNA expression for RORC was significantly increased compared to controls and the 
monocytes from PD patients (Fig. 3B, paper IV).  
The pathological IL-17A production by LCH monocytes can potentially be explained by 
recently discovered mutations in the BRAF gene in LCH lesions that is involved in the Ras-
RAF-MEK-ERK signaling pathway, which regulates among others the production of IL-17A 
(256, 257, 375). The mutation has been identified in blood monocytes and cDC in patients 
with LCH, and suggests that LCH has an neoplastic component causing the inflammatory 
disorder (255, 257). Targeting the BRAF or the whole fraction of monocytes in LCH, have 
shown promising results in vitro and in vivo (264, 376). To study the effect of a specific 
BRAF mutation, V600, on monocyte function including IL-17A production, we are currently 
working on optimizing a protocol for transducing human primary monocytes with BRAFV600. 
In addition to analyzing the direct effect of introducing BRAFV600 into monocytes, we will 
also implant such monocytes in our 3D tissue models for the purpose of studying the impact 
on tissue inflammation, remodeling and pathology.   
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5 CONCLUDING REMARKS AND FUTURE ASPECTS 
 
Chronic inflammatory diseases affect a large number of individuals worldwide and the 
immunopathology that results from the inflammatory reactions cause irreversible tissue 
damage, leading to decreased functionality and quality of life for the individuals affected. By 
increasing the understanding on the role of monocytes in chronic inflammatory diseases, we 
anticipated to identify mechanisms by which these cells can be modulated or targeted, in 
order to attenuate the inflammation and subsequent immunopathology. 
 
The main findings and achievements in my thesis work were: 
 
• PD gingiva presented with an increased inflammatory (COX2, TNF and DC-SIGN) 
and tissue remodelling (MMP12) activity 
 
• Monocyte-derived cells from PD gingiva were identified as the main producers of 
MMP12, acompanied by decreased CD200R surface expression  
 
• The CD200/CD200R pathway was shown to be involved in the regulation of  
MMP12 production by monocyte-derived cells 
 
• Inflamed 3D tissue models of oral and lung mucosa were developed to study human 
monocyte-derived cells in a physiologically relevant milieu 
 
• The levels of MMP12 in saliva were associated with increased percentage of gingival 
pockets with pathological depths 
 
• S100A8/A9 and S100A12 levels in saliva were associated with increased gingival 
inflammation 
 
• Blood monocytes from LCH patients produced IL-17A 
 
These findings and accomplishments have identified functions and pathways, as well as 
established methods that form the basis for future studies aimed at developing 
immunomodulatory treatments of chronic inflammatory diseases. However, there is still 
much to learn about the various monocyte subsets found in humans, and we believe that our 
newly developed tissue model systems can be valuable tools in such studies. As mentioned 
earlier, it would be interesting to sort and implant the three distinct monocyte subsets into the 
tissue models, and study their respective survival capacity and functional behavior in 
response to various stimuli. We believe that the 3D tissue models can be used to study how 
specific mutations in monocytes impact on tissue inflammation and homeostasis. In addition, 
3D models with a combination of monocytes and other immune cells, such as tissue-resident 
macrophages, could give information about the interplay and the distinct roles the respective 
cells have during responses to microbial stimuli and the resolution phase of inflammation. In 
this context, it would also be interesting to introduce, for example, fibroblasts from 
individuals with specific diseases and study the effect on the innate immune cells.   
   49 
6 ACKNOWLEDGEMENTS 
I would like to express my great gratitude to Karolinska Institutet for hosting me since 2007, 
both as a Dental- and a PhD-student, as part of the Clinical Scientist Training Program. 
Without all the funding agencies this work would not have been possible therefore I would 
like to thank the Swedish Dental Society, Patentmedelsfonden, and all funding agencies that 
have supported my supervisors. 
There are a numerous of people that have contributed to the work included in this thesis, 
whom I would like to give my thanks to:  
All patients and healthy volunteers, for participating in the studies. 
Everyone at Center for Infectious Medicine, for making it such an inspiring place to work at, 
I have learned so much during these years. I’m so glad to have had you all as colleagues; you 
have encouraged me to learn complex methods and aroused a curiosity in me for further 
understanding the wide field of Immunology. Hans-Gustaf Ljunggren, you made a great job 
creating this wonderful environment, which has been excellently preserved by the work from 
Anna Norrby-Teglund, Malin Flodström Tullberg and Johan Sandberg. 
The Division of Periodontology, for all the help and the space to perform some of my 
experiments. 
Mattias Svensson, my main supervisor, for adopting me as a master student and later as a 
PhD-student. You have been an excellent supervisor and coach during these years, and 
helped me to grow scientifically and as a person. You have encouraged me to believe in my 
self and my knowledge and inspired me with your enthusiasm and visions. Another strength 
with you is that you always take time to meet and discuss. I really appreciate that you took 
every task seriously and reviewed presentations, abstracts and manuscripts in detail an always 
came with suggestions. Our writing session has help a lot for the development of my writing 
skills. I see a lot of my self in you, but at the same time we are each other’s opposite, me 
being constantly stressed, and you, always calm with a solution for everything. I think that we 
have been a great team.  
Elisabeth Almer Boström, for arriving to my PhD-education when I needed support in the 
lab. You have been a fantastic co-supervisor and I hope that we will continue to do research 
together.  
Anders Gustafsson, for teaching me critical thinking, and for all your knowledge that you 
have shared during our discussions.  
Oscar Hammarfjord, for introducing me to CIM and supervising me during the course that I 
spent at CIM during my Dentistry studies. You have been a great inspiration to me. I would 
also like to thank you for being a co-supervisor in the start of my PhD-studies.  
  50 
The Svensson group: Egle, always full of energy and amazing ideas, thank you for all the 
laughter and tears shared and for all scientific discussions and visions. We started our trip 
together at the KI summer research school in 2010 and have travelled together since; I wish 
you the best of luck on your future research journey. Puran, I kind of always wanted to be 
more like you, so intelligent. I admire you’re way of critical thinking, curiosity, creativity and 
all your knowledge, thanks for sharing it! Magda, I’m so impressed of how you managed to 
handle both family and work. Thank you for everything that I have learned from you and for 
our exciting collaborations. The previous Svensson group members: Anh Thu, you always 
had an answer and learned me so much about the lab work and the modeling work. Julius, for 
all the discussions and help in the lab. Finally, I would like to thank all of you for the support 
and for the expertise that you have shared with me, without you I wouldn’t have been where I 
am today, about to defend my thesis! 
Reuben, Stephanie, Ronaldo, Mirjam and Daniela, present and past members of the Boström 
group, for all the collaborations, all the help and the time spent together, I have learned so 
much from you guys and I really enjoy your company! 
Everyone at Danakliniken, for all the help around sample collections, especially Gunnar and 
Kerstin, for all your efforts and for always being so warm and welcoming, even though I 
know that your schedule was really hectic.  
All the co-authors on the manuscripts and articles, for all the exciting collaborations, it 
worked out really well!  
Kåre Buhlin, my mentor, for taking time to discuss carrier and life with me, you have been a 
great support. 
Patricia De Palma, for your concern, interest and your help in sample collections.  
All Green lab members, for a great working environment, for sharing of reagents and 
knowledge, and for exciting collaborations.  
The Norrby-Teglund group through the years I’ve been around, for shared knowledge and 
reagents. A special thanks to Srikanth for everything you have learned me about chemicals, 
the 3D model experiments and lab work in general.  
Past and current FACS people, especially Martin and Sandra, for teaching me flow cytometry 
and for the help in tackling compensation issues. To all the persons that have been 
responsible since then, you do a great job!  
The “pregnancy” office, without you I would maybe not have had my fantastic son, thank 
you for all the hormones ;). Thank you for the nice environment and even though we have 
been so many in that small room, we have been getting along very well. Christine and Nicole, 
you have been great desk neighbors!  
Joana and Julia, for all the support around the dissertation process. 
   51 
Margit, Lena, Anette and Elisabeth, for taking care of CIM and for making sure that 
everything run smoothly.   
My other employer, Distriktstandvården, and all the colleagues there, for being so 
understanding and for making it possible to adjust my schedule to make it fit with my PhD-
studies.  
To all my friends and relatives outside work, for all your support and understanding! I would 
like to give a special thank to Lisa, I’m so glad to have you as a friend, you have been a great 
support during this period, to me you are like a sister. 
Monica and Bernt, my parents in law, for all your support and love! 
Anton and Axel, I’m so glad to have you as brothers, growing up with you have never been 
boring! Thank you for your support, I’m so excited to show you what I have been working 
with all these years. Anton and Hanna, I hope the baby will stay in till due date, so that you 
can attend the dissertation.  
Mamma och Pappa, for always being there for me, for all your love and support, and for 
always believing in me. Mamma, thank you for all the help during the last hectic time of this 
thesis work, and I can honestly say that without you this would not have been possible!  
Last but not least, my family, Fredrik and Henning, for all the love and support, the tolerance 
for my long working days. Thank you for listening to my talk about failed or successful 
experiments and for your encouragement. You have been my strength through this process 
and I hope that we will get to spend more time together now and I look forward to our new 
adventures.   
  52 
7 REFERENCES 
1. Janeway CA, Jr. & Medzhitov R (2002) Innate immune recognition. Annu Rev 
Immunol 20:197-216. 
2. Abreu MT (2010) Toll-like receptor signalling in the intestinal epithelium: how 
bacterial recognition shapes intestinal function. Nat Rev Immunol 10(2):131-144. 
3. Saenz SA, Taylor BC, & Artis D (2008) Welcome to the neighborhood: epithelial 
cell-derived cytokines license innate and adaptive immune responses at mucosal sites. 
Immunol Rev 226:172-190. 
4. Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 
16(9):582-598. 
5. Rescigno M, et al. (2001) Dendritic cells express tight junction proteins and penetrate 
gut epithelial monolayers to sample bacteria. Nat Immunol 2(4):361-367. 
6. Gordon S (2008) Elie Metchnikoff: father of natural immunity. Eur J Immunol 
38(12):3257-3264. 
7. Bulfone-Paus S, Nilsson G, Draber P, Blank U, & Levi-Schaffer F (2017) Positive 
and Negative Signals in Mast Cell Activation. Trends Immunol 38(9):657-667. 
8. Brinkmann V, et al. (2004) Neutrophil extracellular traps kill bacteria. Science 
303(5663):1532-1535. 
9. Takeda K, Kaisho T, & Akira S (2003) Toll-like receptors. Annu Rev Immunol 
21:335-376. 
10. Mildner A & Jung S (2014) Development and function of dendritic cell subsets. 
Immunity 40(5):642-656. 
11. Ziegler-Heitbrock L, et al. (2010) Nomenclature of monocytes and dendritic cells in 
blood. Blood 116(16):e74-80. 
12. Newson J, et al. (2014) Resolution of acute inflammation bridges the gap between 
innate and adaptive immunity. Blood 124(11):1748-1764. 
13. Jakubzick C, et al. (2013) Minimal differentiation of classical monocytes as they 
survey steady-state tissues and transport antigen to lymph nodes. Immunity 39(3):599-
610. 
14. Chovatiya R & Medzhitov R (2014) Stress, inflammation, and defense of 
homeostasis. Mol Cell 54(2):281-288. 
15. Iwasaki A & Medzhitov R (2015) Control of adaptive immunity by the innate 
immune system. Nat Immunol 16(4):343-353. 
16. Karre K, Ljunggren HG, Piontek G, & Kiessling R (1986) Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defence strategy. Nature 
319(6055):675-678. 
17. Gao Y & Williams AP (2015) Role of Innate T Cells in Anti-Bacterial Immunity. 
Front Immunol 6:302. 
18. Sonnenberg GF, et al. (2012) Innate lymphoid cells promote anatomical containment 
of lymphoid-resident commensal bacteria. Science 336(6086):1321-1325. 
   53 
19. Tait Wojno ED & Artis D (2016) Emerging concepts and future challenges in innate 
lymphoid cell biology. J Exp Med 213(11):2229-2248. 
20. Dunkelberger JR & Song WC (2010) Complement and its role in innate and adaptive 
immune responses. Cell Res 20(1):34-50. 
21. Medzhitov R (2007) Recognition of microorganisms and activation of the immune 
response. Nature 449(7164):819-826. 
22. Hirano M, Das S, Guo P, & Cooper MD (2011) The evolution of adaptive immunity 
in vertebrates. Adv Immunol 109:125-157. 
23. Smith-Garvin JE, Koretzky GA, & Jordan MS (2009) T cell activation. Annu Rev 
Immunol 27:591-619. 
24. Waterhouse NJ, Clarke CJ, Sedelies KA, Teng MW, & Trapani JA (2004) Cytotoxic 
lymphocytes; instigators of dramatic target cell death. Biochem Pharmacol 
68(6):1033-1040. 
25. Kaplan MH, Hufford MM, & Olson MR (2015) The development and in vivo 
function of T helper 9 cells. Nat Rev Immunol 15(5):295-307. 
26. Hirahara K & Nakayama T (2016) CD4+ T-cell subsets in inflammatory diseases: 
beyond the Th1/Th2 paradigm. Int Immunol 28(4):163-171. 
27. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, & Sallusto F (2009) Production of 
interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T 
cells. Nat Immunol 10(8):857-863. 
28. Park CO & Kupper TS (2015) The emerging role of resident memory T cells in 
protective immunity and inflammatory disease. Nat Med 21(7):688-697. 
29. Kurosaki T, Kometani K, & Ise W (2015) Memory B cells. Nat Rev Immunol 
15(3):149-159. 
30. Forthal DN (2014) Functions of Antibodies. Microbiol Spectr 2(4):1-17. 
31. Bellaguarda E & Chang EB (2015) IBD and the gut microbiota--from bench to 
personalized medicine. Curr Gastroenterol Rep 17(4):15. 
32. Darveau RP (2010) Periodontitis: a polymicrobial disruption of host homeostasis. Nat 
Rev Microbiol 8(7):481-490. 
33. Bartold PM & Van Dyke TE (2013) Periodontitis: a host-mediated disruption of 
microbial homeostasis. Unlearning learned concepts. Periodontol 2000 62(1):203-
217. 
34. Geissmann F, et al. (2010) Development of monocytes, macrophages, and dendritic 
cells. Science 327(5966):656-661. 
35. Lambert C, Preijers F, Yanikkaya Demirel G, & Sack U (2017) Monocytes and 
macrophages in flow: an ESCCA initiative on advanced analyses of monocyte lineage 
using flow cytometry. Cytometry B Clin Cytom 92(3):180-188. 
36. Patel AA, et al. (2017) The fate and lifespan of human monocyte subsets in steady 
state and systemic inflammation. J Exp Med 214(7):1913-1923. 
37. van Furth R & Cohn ZA (1968) The origin and kinetics of mononuclear phagocytes. J 
Exp Med 128(3):415-435. 
  54 
38. Passlick B, Flieger D, & Ziegler-Heitbrock HW (1989) Identification and 
characterization of a novel monocyte subpopulation in human peripheral blood. Blood 
74(7):2527-2534. 
39. Zawada AM, et al. (2011) SuperSAGE evidence for CD14++CD16+ monocytes as a 
third monocyte subset. Blood 118(12):e50-61. 
40. Rongvaux A, et al. (2014) Development and function of human innate immune cells 
in a humanized mouse model. Nat Biotechnol 32(4):364-372. 
41. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, & Mathison JC (1990) CD14, a 
receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 
249(4975):1431-1433. 
42. Clarkson SB & Ory PA (1988) CD16. Developmentally regulated IgG Fc receptors 
on cultured human monocytes. J Exp Med 167(2):408-420. 
43. Cros J, et al. (2010) Human CD14dim monocytes patrol and sense nucleic acids and 
viruses via TLR7 and TLR8 receptors. Immunity 33(3):375-386. 
44. Thomas GD, et al. (2017) Human Blood Monocyte Subsets: A New Gating Strategy 
Defined Using Cell Surface Markers Identified by Mass Cytometry. Arterioscler 
Thromb Vasc Biol 37(8):1548-1558. 
45. Boyette LB, et al. (2017) Phenotype, function, and differentiation potential of human 
monocyte subsets. PLoS One 12(4):e0176460. 
46. Ingersoll MA, et al. (2010) Comparison of gene expression profiles between human 
and mouse monocyte subsets. Blood 115(3):e10-19. 
47. Tsou CL, et al. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization 
from bone marrow and recruitment to inflammatory sites. J Clin Invest 117(4):902-
909. 
48. Yona S, et al. (2013) Fate mapping reveals origins and dynamics of monocytes and 
tissue macrophages under homeostasis. Immunity 38(1):79-91. 
49. Wong KL, et al. (2011) Gene expression profiling reveals the defining features of the 
classical, intermediate, and nonclassical human monocyte subsets. Blood 118(5):e16-
31. 
50. Belge KU, et al. (2002) The proinflammatory CD14+CD16+DR++ monocytes are a 
major source of TNF. J Immunol 168(7):3536-3542. 
51. Satpathy AT, et al. (2012) Zbtb46 expression distinguishes classical dendritic cells 
and their committed progenitors from other immune lineages. J Exp Med 
209(6):1135-1152. 
52. Tamoutounour S, et al. (2012) CD64 distinguishes macrophages from dendritic cells 
in the gut and reveals the Th1-inducing role of mesenteric lymph node macrophages 
during colitis. Eur J Immunol 42(12):3150-3166. 
53. Soudja SM, Ruiz AL, Marie JC, & Lauvau G (2012) Inflammatory monocytes 
activate memory CD8(+) T and innate NK lymphocytes independent of cognate 
antigen during microbial pathogen invasion. Immunity 37(3):549-562. 
54. Fullerton JN, Segre E, De Maeyer RP, Maini AA, & Gilroy DW (2016) Intravenous 
Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate 
and Modulate Systemic Inflammation. J Vis Exp (111). 
   55 
55. Gamrekelashvili J, et al. (2016) Regulation of monocyte cell fate by blood vessels 
mediated by Notch signalling. Nat Commun 7:12597. 
56. Carlin LM, et al. (2013) Nr4a1-dependent Ly6C(low) monocytes monitor endothelial 
cells and orchestrate their disposal. Cell 153(2):362-375. 
57. Hanna RN, et al. (2011) The transcription factor NR4A1 (Nur77) controls bone 
marrow differentiation and the survival of Ly6C- monocytes. Nat Immunol 12(8):778-
785. 
58. MacDonald KP, et al. (2010) An antibody against the colony-stimulating factor 1 
receptor depletes the resident subset of monocytes and tissue- and tumor-associated 
macrophages but does not inhibit inflammation. Blood 116(19):3955-3963. 
59. Korkosz M, Bukowska-Strakova K, Sadis S, Grodzicki T, & Siedlar M (2012) 
Monoclonal antibodies against macrophage colony-stimulating factor diminish the 
number of circulating intermediate and nonclassical 
(CD14(++)CD16(+)/CD14(+)CD16(++)) monocytes in rheumatoid arthritis patient. 
Blood 119(22):5329-5330. 
60. Fingerle G, et al. (1993) The novel subset of CD14+/CD16+ blood monocytes is 
expanded in sepsis patients. Blood 82(10):3170-3176. 
61. Grip O, Bredberg A, Lindgren S, & Henriksson G (2007) Increased subpopulations of 
CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. 
Inflamm Bowel Dis 13(5):566-572. 
62. Kawanaka N, et al. (2002) CD14+,CD16+ blood monocytes and joint inflammation 
in rheumatoid arthritis. Arthritis Rheum 46(10):2578-2586. 
63. Merino A, et al. (2011) Senescent CD14+CD16+ monocytes exhibit proinflammatory 
and proatherosclerotic activity. J Immunol 186(3):1809-1815. 
64. Rogacev KS, et al. (2012) CD14++CD16+ monocytes independently predict 
cardiovascular events: a cohort study of 951 patients referred for elective coronary 
angiography. J Am Coll Cardiol 60(16):1512-1520. 
65. Rossol M, Kraus S, Pierer M, Baerwald C, & Wagner U (2012) The CD14(bright) 
CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion 
of the Th17 cell population. Arthritis Rheum 64(3):671-677. 
66. Ziegler-Heitbrock L (2007) The CD14+ CD16+ blood monocytes: their role in 
infection and inflammation. J Leukoc Biol 81(3):584-592. 
67. Green SR, et al. (2006) The CC chemokine MCP-1 stimulates surface expression of 
CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 
MAPK. J Immunol 176(12):7412-7420. 
68. Ancuta P, Wang J, & Gabuzda D (2006) CD16+ monocytes produce IL-6, CCL2, and 
matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial 
cells. J Leukoc Biol 80(5):1156-1164. 
69. Lund H, Boysen P, Akesson CP, Lewandowska-Sabat AM, & Storset AK (2016) 
Transient Migration of Large Numbers of CD14(++) CD16(+) Monocytes to the 
Draining Lymph Node after Onset of Inflammation. Front Immunol 7:322. 
  56 
70. Coffelt SB, et al. (2010) Angiopoietin-2 regulates gene expression in TIE2-expressing 
monocytes and augments their inherent proangiogenic functions. Cancer Res 
70(13):5270-5280. 
71. De Palma M, Murdoch C, Venneri MA, Naldini L, & Lewis CE (2007) Tie2-
expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. 
Trends Immunol 28(12):519-524. 
72. Venneri MA, et al. (2007) Identification of proangiogenic TIE2-expressing 
monocytes (TEMs) in human peripheral blood and cancer. Blood 109(12):5276-5285. 
73. Auffray C, et al. (2007) Monitoring of blood vessels and tissues by a population of 
monocytes with patrolling behavior. Science 317(5838):666-670. 
74. Thomas G, Tacke R, Hedrick CC, & Hanna RN (2015) Nonclassical patrolling 
monocyte function in the vasculature. Arterioscler Thromb Vasc Biol 35(6):1306-
1316. 
75. Minutti CM, Knipper JA, Allen JE, & Zaiss DM (2017) Tissue-specific contribution 
of macrophages to wound healing. Semin Cell Dev Biol 61:3-11. 
76. Murdoch C & Finn A (2000) Chemokine receptors and their role in inflammation and 
infectious diseases. Blood 95(10):3032-3043. 
77. Serbina NV & Pamer EG (2006) Monocyte emigration from bone marrow during 
bacterial infection requires signals mediated by chemokine receptor CCR2. Nat 
Immunol 7(3):311-317. 
78. Shi C & Pamer EG (2011) Monocyte recruitment during infection and inflammation. 
Nat Rev Immunol 11(11):762-774. 
79. Ley K, Laudanna C, Cybulsky MI, & Nourshargh S (2007) Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7(9):678-
689. 
80. Galkina E & Ley K (2007) Vascular adhesion molecules in atherosclerosis. 
Arterioscler Thromb Vasc Biol 27(11):2292-2301. 
81. Shi C, et al. (2010) Monocyte trafficking to hepatic sites of bacterial infection is 
chemokine independent and directed by focal intercellular adhesion molecule-1 
expression. J Immunol 184(11):6266-6274. 
82. Henderson RB, Hobbs JA, Mathies M, & Hogg N (2003) Rapid recruitment of 
inflammatory monocytes is independent of neutrophil migration. Blood 102(1):328-
335. 
83. Kreisel D, et al. (2010) In vivo two-photon imaging reveals monocyte-dependent 
neutrophil extravasation during pulmonary inflammation. Proc Natl Acad Sci U S A 
107(42):18073-18078. 
84. Bain CC, et al. (2013) Resident and pro-inflammatory macrophages in the colon 
represent alternative context-dependent fates of the same Ly6Chi monocyte 
precursors. Mucosal Immunol 6(3):498-510. 
85. Rivollier A, He J, Kole A, Valatas V, & Kelsall BL (2012) Inflammation switches the 
differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to 
inflammatory dendritic cells in the colon. J Exp Med 209(1):139-155. 
   57 
86. Saalbach A, et al. (2015) Fibroblasts support migration of monocyte-derived dendritic 
cells by secretion of PGE2 and MMP-1. Exp Dermatol 24(8):598-604. 
87. Gronski TJ, Jr., et al. (1997) Hydrolysis of a broad spectrum of extracellular matrix 
proteins by human macrophage elastase. J Biol Chem 272(18):12189-12194. 
88. Heinz A, et al. (2010) Degradation of tropoelastin by matrix metalloproteinases--
cleavage site specificities and release of matrikines. FEBS J 277(8):1939-1956. 
89. Guilliams M, et al. (2009) IL-10 dampens TNF/inducible nitric oxide synthase-
producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol 
182(2):1107-1118. 
90. Dal-Secco D, et al. (2015) A dynamic spectrum of monocytes arising from the in situ 
reprogramming of CCR2+ monocytes at a site of sterile injury. J Exp Med 
212(4):447-456. 
91. Mildner A, Yona S, & Jung S (2013) A close encounter of the third kind: monocyte-
derived cells. Adv Immunol 120:69-103. 
92. Segura E, et al. (2013) Human inflammatory dendritic cells induce Th17 cell 
differentiation. Immunity 38(2):336-348. 
93. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, & Pamer EG (2003) 
TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial 
infection. Immunity 19(1):59-70. 
94. Bleriot C, et al. (2015) Liver-resident macrophage necroptosis orchestrates type 1 
microbicidal inflammation and type-2-mediated tissue repair during bacterial 
infection. Immunity 42(1):145-158. 
95. Thornley TB, et al. (2014) Fragile TIM-4-expressing tissue resident macrophages are 
migratory and immunoregulatory. J Clin Invest 124(8):3443-3454. 
96. Varol C, et al. (2007) Monocytes give rise to mucosal, but not splenic, conventional 
dendritic cells. J Exp Med 204(1):171-180. 
97. Tamoutounour S, et al. (2013) Origins and functional specialization of macrophages 
and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity 
39(5):925-938. 
98. Rotta G, et al. (2003) Lipopolysaccharide or whole bacteria block the conversion of 
inflammatory monocytes into dendritic cells in vivo. J Exp Med 198(8):1253-1263. 
99. Ramachandran P, et al. (2012) Differential Ly-6C expression identifies the recruited 
macrophage phenotype, which orchestrates the regression of murine liver fibrosis. 
Proc Natl Acad Sci U S A 109(46):E3186-3195. 
100. Ginhoux F & Jung S (2014) Monocytes and macrophages: developmental pathways 
and tissue homeostasis. Nat Rev Immunol 14(6):392-404. 
101. Bain CC, et al. (2014) Constant replenishment from circulating monocytes maintains 
the macrophage pool in the intestine of adult mice. Nat Immunol 15(10):929-937. 
102. Gomez Perdiguero E, et al. (2015) Tissue-resident macrophages originate from yolk-
sac-derived erythro-myeloid progenitors. Nature 518(7540):547-551. 
103. Jagannathan R, Lavu V, & Rao SR (2014) Comparison of the proportion of non-
classic (CD14+CD16+) monocytes/macrophages in peripheral blood and gingiva of 
  58 
healthy individuals and patients with chronic periodontitis. J Periodontol 85(6):852-
858. 
104. Xue J, et al. (2014) Transcriptome-based network analysis reveals a spectrum model 
of human macrophage activation. Immunity 40(2):274-288. 
105. Gautier EL, et al. (2012) Gene-expression profiles and transcriptional regulatory 
pathways that underlie the identity and diversity of mouse tissue macrophages. Nat 
Immunol 13(11):1118-1128. 
106. Penberthy KK & Ravichandran KS (2016) Apoptotic cell recognition receptors and 
scavenger receptors. Immunol Rev 269(1):44-59. 
107. Huang WC, Sala-Newby GB, Susana A, Johnson JL, & Newby AC (2012) Classical 
macrophage activation up-regulates several matrix metalloproteinases through 
mitogen activated protein kinases and nuclear factor-kappaB. PLoS One 7(8):e42507. 
108. Newby AC (2016) Metalloproteinase production from macrophages - a perfect storm 
leading to atherosclerotic plaque rupture and myocardial infarction. Exp Physiol 
101(11):1327-1337. 
109. Khokha R, Murthy A, & Weiss A (2013) Metalloproteinases and their natural 
inhibitors in inflammation and immunity. Nat Rev Immunol 13(9):649-665. 
110. Quinn JM, Neale S, Fujikawa Y, McGee JO, & Athanasou NA (1998) Human 
osteoclast formation from blood monocytes, peritoneal macrophages, and bone 
marrow cells. Calcif Tissue Int 62(6):527-531. 
111. Komano Y, Nanki T, Hayashida K, Taniguchi K, & Miyasaka N (2006) Identification 
of a human peripheral blood monocyte subset that differentiates into osteoclasts. 
Arthritis Res Ther 8(5):R152. 
112. Gordon S & Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev 
Immunol 5(12):953-964. 
113. Adams DO & Hamilton TA (1984) The cell biology of macrophage activation. Annu 
Rev Immunol 2:283-318. 
114. Mills CD, Kincaid K, Alt JM, Heilman MJ, & Hill AM (2000) M-1/M-2 
macrophages and the Th1/Th2 paradigm. J Immunol 164(12):6166-6173. 
115. Martinez FO, Gordon S, Locati M, & Mantovani A (2006) Transcriptional profiling 
of the human monocyte-to-macrophage differentiation and polarization: new 
molecules and patterns of gene expression. J Immunol 177(10):7303-7311. 
116. Mantovani A, Sozzani S, Locati M, Allavena P, & Sica A (2002) Macrophage 
polarization: tumor-associated macrophages as a paradigm for polarized M2 
mononuclear phagocytes. Trends Immunol 23(11):549-555. 
117. Mantovani A, et al. (2004) The chemokine system in diverse forms of macrophage 
activation and polarization. Trends Immunol 25(12):677-686. 
118. Jaguin M, Houlbert N, Fardel O, & Lecureur V (2013) Polarization profiles of human 
M-CSF-generated macrophages and comparison of M1-markers in classically 
activated macrophages from GM-CSF and M-CSF origin. Cell Immunol 281(1):51-
61. 
119. Vogel DY, et al. (2014) Human macrophage polarization in vitro: maturation and 
activation methods compared. Immunobiology 219(9):695-703. 
   59 
120. Copland DA, et al. (2007) Monoclonal antibody-mediated CD200 receptor signaling 
suppresses macrophage activation and tissue damage in experimental autoimmune 
uveoretinitis. Am J Pathol 171(2):580-588. 
121. Fraser SD, Sadofsky LR, Kaye PM, & Hart SP (2016) Reduced expression of 
monocyte CD200R is associated with enhanced proinflammatory cytokine production 
in sarcoidosis. Sci Rep 6:38689. 
122. Varin A, Pontikoglou C, Labat E, Deschaseaux F, & Sensebe L (2013) 
CD200R/CD200 inhibits osteoclastogenesis: new mechanism of osteoclast control by 
mesenchymal stem cells in human. PLoS One 8(8):e72831. 
123. Walker DG, Dalsing-Hernandez JE, Campbell NA, & Lue LF (2009) Decreased 
expression of CD200 and CD200 receptor in Alzheimer's disease: a potential 
mechanism leading to chronic inflammation. Exp Neurol 215(1):5-19. 
124. Conde P, et al. (2015) DC-SIGN(+) Macrophages Control the Induction of 
Transplantation Tolerance. Immunity 42(6):1143-1158. 
125. Murray PJ, et al. (2014) Macrophage activation and polarization: nomenclature and 
experimental guidelines. Immunity 41(1):14-20. 
126. Okabe Y & Medzhitov R (2016) Tissue biology perspective on macrophages. Nat 
Immunol 17(1):9-17. 
127. Svensson M & Kaye PM (2006) Stromal-cell regulation of dendritic-cell 
differentiation and function. Trends Immunol 27(12):580-587. 
128. Ginhoux F, Schultze JL, Murray PJ, Ochando J, & Biswas SK (2016) New insights 
into the multidimensional concept of macrophage ontogeny, activation and function. 
Nat Immunol 17(1):34-40. 
129. Lavin Y, et al. (2014) Tissue-resident macrophage enhancer landscapes are shaped by 
the local microenvironment. Cell 159(6):1312-1326. 
130. Mosser DM & Edwards JP (2008) Exploring the full spectrum of macrophage 
activation. Nat Rev Immunol 8(12):958-969. 
131. Lawrence T & Natoli G (2011) Transcriptional regulation of macrophage 
polarization: enabling diversity with identity. Nat Rev Immunol 11(11):750-761. 
132. Saeed S, et al. (2014) Epigenetic programming of monocyte-to-macrophage 
differentiation and trained innate immunity. Science 345(6204):1251086. 
133. Hutchinson JA, et al. (2011) Cutting Edge: Immunological consequences and 
trafficking of human regulatory macrophages administered to renal transplant 
recipients. J Immunol 187(5):2072-2078. 
134. Mia S, Warnecke A, Zhang XM, Malmstrom V, & Harris RA (2014) An optimized 
protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a 
dominant immunosuppressive phenotype. Scand J Immunol 79(5):305-314. 
135. Nguyen Hoang AT, et al. (2014) Technical advance: live-imaging analysis of human 
dendritic cell migrating behavior under the influence of immune-stimulating reagents 
in an organotypic model of lung. J Leukoc Biol 96(3):481-489. 
136. Nguyen Hoang AT, et al. (2012) Dendritic cell functional properties in a three-
dimensional tissue model of human lung mucosa. Am J Physiol Lung Cell Mol 
Physiol 302(2):L226-237. 
  60 
137. Bjornfot Holmstrom S, et al. (2017) Gingival Tissue Inflammation Promotes 
Increased Matrix Metalloproteinase-12 Production by CD200Rlow Monocyte-
Derived Cells in Periodontitis. J Immunol. 
138. Hashimoto D, et al. (2013) Tissue-resident macrophages self-maintain locally 
throughout adult life with minimal contribution from circulating monocytes. Immunity 
38(4):792-804. 
139. Guilliams M, et al. (2014) Dendritic cells, monocytes and macrophages: a unified 
nomenclature based on ontogeny. Nat Rev Immunol 14(8):571-578. 
140. Davies LC, et al. (2011) A quantifiable proliferative burst of tissue macrophages 
restores homeostatic macrophage populations after acute inflammation. Eur J 
Immunol 41(8):2155-2164. 
141. Schulz C, et al. (2012) A lineage of myeloid cells independent of Myb and 
hematopoietic stem cells. Science 336(6077):86-90. 
142. Mass E, et al. (2016) Specification of tissue-resident macrophages during 
organogenesis. Science 353(6304). 
143. Sheng J, Ruedl C, & Karjalainen K (2015) Most Tissue-Resident Macrophages 
Except Microglia Are Derived from Fetal Hematopoietic Stem Cells. Immunity 
43(2):382-393. 
144. Bigley V & Collin M (2011) Dendritic cell, monocyte, B and NK lymphoid 
deficiency defines the lost lineages of a new GATA-2 dependent myelodysplastic 
syndrome. Haematologica 96(8):1081-1083. 
145. Haniffa M, et al. (2009) Differential rates of replacement of human dermal dendritic 
cells and macrophages during hematopoietic stem cell transplantation. J Exp Med 
206(2):371-385. 
146. Kanitakis J, Morelon E, Petruzzo P, Badet L, & Dubernard JM (2011) Self-renewal 
capacity of human epidermal Langerhans cells: observations made on a composite 
tissue allograft. Exp Dermatol 20(2):145-146. 
147. Gosselin D & Glass CK (2014) Epigenomics of macrophages. Immunol Rev 
262(1):96-112. 
148. Wang Y, et al. (2012) IL-34 is a tissue-restricted ligand of CSF1R required for the 
development of Langerhans cells and microglia. Nat Immunol 13(8):753-760. 
149. Van Gassen N, et al. (2015) Macrophage dynamics are regulated by local 
macrophage proliferation and monocyte recruitment in injured pancreas. Eur J 
Immunol 45(5):1482-1493. 
150. Lavin Y, Mortha A, Rahman A, & Merad M (2015) Regulation of macrophage 
development and function in peripheral tissues. Nat Rev Immunol 15(12):731-744. 
151. Guilliams M, et al. (2013) Alveolar macrophages develop from fetal monocytes that 
differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med 
210(10):1977-1992. 
152. Sainathan SK, et al. (2008) Granulocyte macrophage colony-stimulating factor 
ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis 14(1):88-99. 
   61 
153. Ajami B, Bennett JL, Krieger C, McNagny KM, & Rossi FM (2011) Infiltrating 
monocytes trigger EAE progression, but do not contribute to the resident microglia 
pool. Nat Neurosci 14(9):1142-1149. 
154. Davies LC, Jenkins SJ, Allen JE, & Taylor PR (2013) Tissue-resident macrophages. 
Nat Immunol 14(10):986-995. 
155. Davies LC, et al. (2013) Distinct bone marrow-derived and tissue-resident 
macrophage lineages proliferate at key stages during inflammation. Nat Commun 
4:1886. 
156. Epelman S, et al. (2014) Embryonic and adult-derived resident cardiac macrophages 
are maintained through distinct mechanisms at steady state and during inflammation. 
Immunity 40(1):91-104. 
157. Zhao Y, et al. (2014) Thrombospondin-1 triggers macrophage IL-10 production and 
promotes resolution of experimental lung injury. Mucosal Immunol 7(2):440-448. 
158. McGrath EE, et al. (2011) TNF-related apoptosis-inducing ligand (TRAIL) regulates 
inflammatory neutrophil apoptosis and enhances resolution of inflammation. J Leukoc 
Biol 90(5):855-865. 
159. Fahrenhold M, et al. (2017) Trem2 Expression in the Human Brain: A Marker of 
Monocyte Recruitment? Brain Pathol. 
160. Baharom F, Rankin G, Blomberg A, & Smed-Sorensen A (2017) Human Lung 
Mononuclear Phagocytes in Health and Disease. Front Immunol 8:499. 
161. Takata K, et al. (2017) Induced-Pluripotent-Stem-Cell-Derived Primitive 
Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage 
Differentiation and Function. Immunity 47(1):183-198 e186. 
162. Awang RA, et al. (2014) Clinical associations between IL-17 family cytokines and 
periodontitis and potential differential roles for IL-17A and IL-17E in periodontal 
immunity. Inflamm Res 63(12):1001-1012. 
163. Coury F, et al. (2008) Langerhans cell histiocytosis reveals a new IL-17A-dependent 
pathway of dendritic cell fusion. Nat Med 14(1):81-87. 
164. Lourda M, et al. (2014) Detection of IL-17A-producing peripheral blood monocytes 
in Langerhans cell histiocytosis patients. Clin Immunol 153(1):112-122. 
165. Facciolo MT, Riva F, Gallenzi P, Patini R, & Gaglioti D (2017) A rare case of oral 
multisystem Langerhans cell histiocytosis. J Clin Exp Dent 9(6):e820-e824. 
166. Panis V, et al. (2016) Langerhans cell histiocytosis mimicking aggressive 
periodontitis: Challenges in diagnosis and management. Quintessence Int 47(9):731-
738. 
167. Bye FL & Caffesse RG (1979) The process of keratinization of the gingival 
epithelium. J West Soc Periodontol Periodontal Abstr 27(3):72-85. 
168. Hoytema van Konijnenburg DP, et al. (2017) Intestinal Epithelial and Intraepithelial 
T Cell Crosstalk Mediates a Dynamic Response to Infection. Cell. 
169. Seguier S, Bodineau A, Godeau G, Pellat B, & Brousse N (2003) Langerin+ versus 
CD1a+ Langerhans cells in human gingival tissue: a comparative and quantitative 
immunohistochemical study. Arch Oral Biol 48(4):255-262. 
  62 
170. Dutzan N, Konkel JE, Greenwell-Wild T, & Moutsopoulos NM (2016) 
Characterization of the human immune cell network at the gingival barrier. Mucosal 
Immunol 9(5):1163-1172. 
171. Artese L, et al. (2011) Immunohistochemical analysis of inflammatory infiltrate in 
aggressive and chronic periodontitis: a comparative study. Clin Oral Investig 
15(2):233-240. 
172. Carcuac O & Berglundh T (2014) Composition of human peri-implantitis and 
periodontitis lesions. J Dent Res 93(11):1083-1088. 
173. Lamster IB (1997) Evaluation of components of gingival crevicular fluid as 
diagnostic tests. Ann Periodontol 2(1):123-137. 
174. Loe H, Theilade E, & Jensen SB (1965) Experimental Gingivitis in Man. J 
Periodontol 36:177-187. 
175. Hugoson A, Sjodin B, & Norderyd O (2008) Trends over 30 years, 1973-2003, in the 
prevalence and severity of periodontal disease. J Clin Periodontol 35(5):405-414. 
176. Papapanou PN (2012) The prevalence of periodontitis in the US: forget what you 
were told. J Dent Res 91(10):907-908. 
177. Armitage GC (1999) Development of a classification system for periodontal diseases 
and conditions. Ann Periodontol 4(1):1-6. 
178. Anonymous (2015) American Academy of Periodontology Task Force Report on the 
Update to the 1999 Classification of Periodontal Diseases and Conditions. J 
Periodontol 86(7):835-838. 
179. Kinane DF, Stathopoulou PG, & Papapanou PN (2017) Periodontal diseases. Nat Rev 
Dis Primers 3:17038. 
180. Bi J, et al. (2017) Suppression of alphavbeta6 Integrin Expression by Polymicrobial 
Oral Biofilms in Gingival Epithelial Cells. Sci Rep 7(1):4411. 
181. Bosshardt DD & Lang NP (2005) The junctional epithelium: from health to disease. J 
Dent Res 84(1):9-20. 
182. Buduneli N & Kinane DF (2011) Host-derived diagnostic markers related to soft 
tissue destruction and bone degradation in periodontitis. J Clin Periodontol 38 Suppl 
11:85-105. 
183. Sorsa T, et al. (2006) Matrix metalloproteinases: contribution to pathogenesis, 
diagnosis and treatment of periodontal inflammation. Ann Med 38(5):306-321. 
184. Page RC & Kornman KS (1997) The pathogenesis of human periodontitis: an 
introduction. Periodontol 2000 14:9-11. 
185. Hajishengallis G (2014) Immunomicrobial pathogenesis of periodontitis: keystones, 
pathobionts, and host response. Trends Immunol 35(1):3-11. 
186. Kassebaum NJ, et al. (2014) Global burden of severe periodontitis in 1990-2010: a 
systematic review and meta-regression. J Dent Res 93(11):1045-1053. 
187. Jiao Y, et al. (2013) Induction of bone loss by pathobiont-mediated Nod1 signaling in 
the oral cavity. Cell Host Microbe 13(5):595-601. 
   63 
188. Offenbacher S, et al. (2007) Periodontal disease at the biofilm-gingival interface. J 
Periodontol 78(10):1911-1925. 
189. Haririan H, et al. (2017) Salivary Neuropeptides, Stress and Periodontitis. J 
Periodontol:1-15. 
190. Keller A, Rohde JF, Raymond K, & Heitmann BL (2015) Association between 
periodontal disease and overweight and obesity: a systematic review. J Periodontol 
86(6):766-776. 
191. Laine ML, Crielaard W, & Loos BG (2012) Genetic susceptibility to periodontitis. 
Periodontol 2000 58(1):37-68. 
192. Lindroth AM & Park YJ (2013) Epigenetic biomarkers: a step forward for 
understanding periodontitis. J Periodontal Implant Sci 43(3):111-120. 
193. Stabholz A, Soskolne WA, & Shapira L (2010) Genetic and environmental risk 
factors for chronic periodontitis and aggressive periodontitis. Periodontol 2000 
53:138-153. 
194. Martins MD, et al. (2016) Epigenetic Modifications of Histones in Periodontal 
Disease. J Dent Res 95(2):215-222. 
195. Nociti FH, Jr., Casati MZ, & Duarte PM (2015) Current perspective of the impact of 
smoking on the progression and treatment of periodontitis. Periodontol 2000 
67(1):187-210. 
196. Abusleme L, et al. (2013) The subgingival microbiome in health and periodontitis and 
its relationship with community biomass and inflammation. ISME J 7(5):1016-1025. 
197. Hasturk H, et al. (2007) Resolvin E1 regulates inflammation at the cellular and tissue 
level and restores tissue homeostasis in vivo. J Immunol 179(10):7021-7029. 
198. Tonetti MS, Chapple IL, & Working Group 3 of Seventh European Workshop on P 
(2011) Biological approaches to the development of novel periodontal therapies--
consensus of the Seventh European Workshop on Periodontology. J Clin Periodontol 
38 Suppl 11:114-118. 
199. Hasturk H, Kantarci A, & Van Dyke TE (2012) Paradigm shift in the 
pharmacological management of periodontal diseases. Front Oral Biol 15:160-176. 
200. Caton J & Ryan ME (2011) Clinical studies on the management of periodontal 
diseases utilizing subantimicrobial dose doxycycline (SDD). Pharmacol Res 
63(2):114-120. 
201. Shiloah J, et al. (2014) The effect of long-term aspirin intake on the outcome of non-
surgical periodontal therapy in smokers: a double-blind, randomized pilot study. J 
Periodontal Res 49(1):102-109. 
202. El-Sharkawy H, et al. (2010) Adjunctive treatment of chronic periodontitis with daily 
dietary supplementation with omega-3 Fatty acids and low-dose aspirin. J 
Periodontol 81(11):1635-1643. 
203. Flemmig TF, Rumetsch M, & Klaiber B (1996) Efficacy of systemically administered 
acetylsalicylic acid plus scaling on periodontal health and elastase-alpha 1-proteinase 
inhibitor in gingival crevicular fluid. J Clin Periodontol 23(3 Pt 1):153-159. 
204. Yen CA, et al. (2008) The effect of a selective cyclooxygenase-2 inhibitor (celecoxib) 
on chronic periodontitis. J Periodontol 79(1):104-113. 
  64 
205. Artis D (2008) Epithelial-cell recognition of commensal bacteria and maintenance of 
immune homeostasis in the gut. Nat Rev Immunol 8(6):411-420. 
206. Naik S, et al. (2015) Commensal-dendritic-cell interaction specifies a unique 
protective skin immune signature. Nature 520(7545):104-108. 
207. Nassar M, et al. (2017) GAS6 is a key homeostatic immunological regulator of host-
commensal interactions in the oral mucosa. Proc Natl Acad Sci U S A 114(3):E337-
E346. 
208. Ueda Y, et al. (2010) Commensal microbiota induce LPS hyporesponsiveness in 
colonic macrophages via the production of IL-10. Int Immunol 22(12):953-962. 
209. Moutsopoulos NM & Konkel JE (2017) Tissue-Specific Immunity at the Oral 
Mucosal Barrier. Trends Immunol. 
210. Buskermolen JK, Janus MM, Roffel S, Krom BP, & Gibbs S (2017) Saliva-Derived 
Commensal and Pathogenic Biofilms in a Human Gingiva Model. J Dent 
Res:22034517729998. 
211. Dickinson BC, et al. (2011) Interaction of oral bacteria with gingival epithelial cell 
multilayers. Mol Oral Microbiol 26(3):210-220. 
212. Ji S, Kim Y, Min BM, Han SH, & Choi Y (2007) Innate immune responses of 
gingival epithelial cells to nonperiodontopathic and periodontopathic bacteria. J 
Periodontal Res 42(6):503-510. 
213. Conti HR, et al. (2016) IL-17 Receptor Signaling in Oral Epithelial Cells Is Critical 
for Protection against Oropharyngeal Candidiasis. Cell Host Microbe 20(5):606-617. 
214. Dutzan N, et al. (2017) On-going Mechanical Damage from Mastication Drives 
Homeostatic Th17 Cell Responses at the Oral Barrier. Immunity 46(1):133-147. 
215. Veldhoen M (2017) Th17 Cells Require You to Chew before You Swallow. Immunity 
46(1):8-10. 
216. Cheng WC, Hughes FJ, & Taams LS (2014) The presence, function and regulation of 
IL-17 and Th17 cells in periodontitis. J Clin Periodontol 41(6):541-549. 
217. Allam JP, et al. (2011) IL-23-producing CD68(+) macrophage-like cells predominate 
within an IL-17-polarized infiltrate in chronic periodontitis lesions. J Clin Periodontol 
38(10):879-886. 
218. Fragoulis GE, Siebert S, & McInnes IB (2016) Therapeutic Targeting of IL-17 and 
IL-23 Cytokines in Immune-Mediated Diseases. Annu Rev Med 67:337-353. 
219. Ohyama H, et al. (2009) The involvement of IL-23 and the Th17 pathway in 
periodontitis. J Dent Res 88(7):633-638. 
220. Benakanakere M & Kinane DF (2012) Innate cellular responses to the periodontal 
biofilm. Front Oral Biol 15:41-55. 
221. Graves D (2008) Cytokines that promote periodontal tissue destruction. J Periodontol 
79(8 Suppl):1585-1591. 
222. Kinane DF, Demuth DR, Gorr SU, Hajishengallis GN, & Martin MH (2007) Human 
variability in innate immunity. Periodontol 2000 45:14-34. 
   65 
223. Delima AJ & Van Dyke TE (2003) Origin and function of the cellular components in 
gingival crevice fluid. Periodontol 2000 31:55-76. 
224. Eskan MA, et al. (2012) The leukocyte integrin antagonist Del-1 inhibits IL-17-
mediated inflammatory bone loss. Nat Immunol 13(5):465-473. 
225. Ariel A & Serhan CN (2012) New Lives Given by Cell Death: Macrophage 
Differentiation Following Their Encounter with Apoptotic Leukocytes during the 
Resolution of Inflammation. Front Immunol 3:4. 
226. Ley K (2017) Breaking a Vicious Cycle. N Engl J Med 376(12):1172-1174. 
227. Moutsopoulos NM, et al. (2017) Interleukin-12 and Interleukin-23 Blockade in 
Leukocyte Adhesion Deficiency Type 1. N Engl J Med 376(12):1141-1146. 
228. Uderhardt S, et al. (2012) 12/15-lipoxygenase orchestrates the clearance of apoptotic 
cells and maintains immunologic tolerance. Immunity 36(5):834-846. 
229. Benakanakere M, Abdolhosseini M, Hosur K, Finoti LS, & Kinane DF (2015) TLR2 
promoter hypermethylation creates innate immune dysbiosis. J Dent Res 94(1):183-
191. 
230. Arizon M, et al. (2012) Langerhans cells down-regulate inflammation-driven alveolar 
bone loss. Proc Natl Acad Sci U S A 109(18):7043-7048. 
231. Shklovskaya E, et al. (2011) Langerhans cells are precommitted to immune tolerance 
induction. Proc Natl Acad Sci U S A 108(44):18049-18054. 
232. Anjana R, Joseph L, & Suresh R (2012) Immunohistochemical localization of CD1a 
and S100 in gingival tissues of healthy and chronic periodontitis subjects. Oral Dis 
18(8):778-785. 
233. Hoeffel G, et al. (2012) Adult Langerhans cells derive predominantly from embryonic 
fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J 
Exp Med 209(6):1167-1181. 
234. Lamarque S, et al. (2004) Gingival organotypic culture and langerhans cells: a tool 
for immunotoxicologic experiments. J Biomed Mater Res A 68(2):257-263. 
235. Bostrom EA, et al. (2015) Increased Eotaxin and MCP-1 Levels in Serum from 
Individuals with Periodontitis and in Human Gingival Fibroblasts Exposed to Pro-
Inflammatory Cytokines. PLoS One 10(8):e0134608. 
236. Stadler AF, et al. (2016) Gingival crevicular fluid levels of cytokines/chemokines in 
chronic periodontitis: a meta-analysis. J Clin Periodontol 43(9):727-745. 
237. Liu YZ, et al. (2016) RNA-sequencing study of peripheral blood monocytes in 
chronic periodontitis. Gene 581(2):152-160. 
238. Papapanou PN, et al. (2007) Periodontal therapy alters gene expression of peripheral 
blood monocytes. J Clin Periodontol 34(9):736-747. 
239. Berker E, Kantarci A, Hasturk H, & Van Dyke TE (2013) Blocking proinflammatory 
cytokine release modulates peripheral blood mononuclear cell response to 
Porphyromonas gingivalis. J Periodontol 84(9):1337-1345. 
240. Cury PR, Carmo JP, Horewicz VV, Santos JN, & Barbuto JA (2013) Altered 
phenotype and function of dendritic cells in individuals with chronic periodontitis. 
Arch Oral Biol 58(9):1208-1216. 
  66 
241. Carrion J, et al. (2012) Microbial carriage state of peripheral blood dendritic cells 
(DCs) in chronic periodontitis influences DC differentiation, atherogenic potential. J 
Immunol 189(6):3178-3187. 
242. Nagasawa T, et al. (2004) Expression of CD14, CD16 and CD45RA on monocytes 
from periodontitis patients. J Periodontal Res 39(1):72-78. 
243. Nicu EA, van der Velden U, Everts V, & Loos BG (2008) Expression of FcgammaRs 
and mCD14 on polymorphonuclear neutrophils and monocytes may determine 
periodontal infection. Clin Exp Immunol 154(2):177-186. 
244. Cheng WC, et al. (2016) Periodontitis-associated pathogens P. gingivalis and A. 
actinomycetemcomitans activate human CD14(+) monocytes leading to enhanced 
Th17/IL-17 responses. Eur J Immunol 46(9):2211-2221. 
245. Herrera BS, et al. (2014) Peripheral blood mononuclear phagocytes from patients 
with chronic periodontitis are primed for osteoclast formation. J Periodontol 
85(4):e72-81. 
246. Lin D, et al. (2014) IL-17 regulates the expressions of RANKL and OPG in human 
periodontal ligament cells via TRAF6/TBK1-JNK/NF-kappaB pathways. 
Immunology. 
247. Belibasakis GN & Bostanci N (2012) The RANKL-OPG system in clinical 
periodontology. J Clin Periodontol 39(3):239-248. 
248. Lundmark A, et al. (2015) Transcriptome analysis reveals mucin 4 to be highly 
associated with periodontitis and identifies pleckstrin as a link to systemic diseases. 
Sci Rep 5:18475. 
249. Yang J, et al. (2017) Enhanced activity of macrophage M1/M2 phenotypes in 
periodontitis. Arch Oral Biol. 
250. Wynn TA, Chawla A, & Pollard JW (2013) Macrophage biology in development, 
homeostasis and disease. Nature 496(7446):445-455. 
251. Steinmetz O, et al. (2016) CX3CR1hi Monocyte/Macrophages Support Bacterial 
Survival and Experimental Infection-Driven Bone Resorption. J Infect Dis 
213(9):1505-1515. 
252. Lam RS, et al. (2015) GM-CSF and uPA are required for Porphyromonas gingivalis-
induced alveolar bone loss in a mouse periodontitis model. Immunol Cell Biol 
93(8):705-715. 
253. Stalemark H, et al. (2008) Incidence of Langerhans cell histiocytosis in children: a 
population-based study. Pediatr Blood Cancer 51(1):76-81. 
254. Willman CL, et al. (1994) Langerhans'-cell histiocytosis (histiocytosis X)--a clonal 
proliferative disease. N Engl J Med 331(3):154-160. 
255. Berres ML, et al. (2014) BRAF-V600E expression in precursor versus differentiated 
dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211(4):669-683. 
256. Sahm F, et al. (2012) BRAFV600E mutant protein is expressed in cells of variable 
maturation in Langerhans cell histiocytosis. Blood 120(12):e28-34. 
257. Milne P, et al. (2017) Hematopoietic origin of Langerhans cell histiocytosis and 
Erdheim-Chester disease in adults. Blood 130(2):167-175. 
   67 
258. Collin M, Bigley V, McClain KL, & Allen CE (2015) Cell(s) of Origin of Langerhans 
Cell Histiocytosis. Hematol Oncol Clin North Am 29(5):825-838. 
259. Allen CE, et al. (2010) Cell-specific gene expression in Langerhans cell histiocytosis 
lesions reveals a distinct profile compared with epidermal Langerhans cells. J 
Immunol 184(8):4557-4567. 
260. Hoshino N, et al. (2005) A novel role for Notch ligand Delta-1 as a regulator of 
human Langerhans cell development from blood monocytes. J Leukoc Biol 
78(4):921-929. 
261. Murakami I, et al. (2013) IL-17A receptor expression differs between subclasses of 
Langerhans cell histiocytosis, which might settle the IL-17A controversy. Virchows 
Arch 462(2):219-228. 
262. da Costa CE, et al. (2005) Presence of osteoclast-like multinucleated giant cells in the 
bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 201(5):687-
693. 
263. Rust R, et al. (2006) Gene expression analysis of dendritic/Langerhans cells and 
Langerhans cell histiocytosis. J Pathol 209(4):474-483. 
264. Lourda M, et al. (2016) Adsorptive depletion of blood monocytes reduces the levels 
of circulating interleukin-17A in Langerhans cell histiocytosis. Blood 128(9):1302-
1305. 
265. Bokhari SA, et al. (2014) Periodontitis in coronary heart disease patients: strong 
association between bleeding on probing and systemic biomarkers. J Clin Periodontol 
41(11):1048-1054. 
266. Tonetti MS, Van Dyke TE, & Working group 1 of the joint EFPAAPw (2013) 
Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint 
EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontol 40 
Suppl 14:S24-29. 
267. Tonetti MS, et al. (2007) Treatment of periodontitis and endothelial function. N Engl 
J Med 356(9):911-920. 
268. Urra X, et al. (2009) Monocyte subtypes predict clinical course and prognosis in 
human stroke. J Cereb Blood Flow Metab 29(5):994-1002. 
269. Krychtiuk KA, et al. (2014) Small high-density lipoprotein is associated with 
monocyte subsets in stable coronary artery disease. Atherosclerosis 237(2):589-596. 
270. Berg KE, et al. (2012) Elevated CD14++CD16- monocytes predict cardiovascular 
events. Circ Cardiovasc Genet 5(1):122-131. 
271. Ross R (1999) Atherosclerosis--an inflammatory disease. N Engl J Med 340(2):115-
126. 
272. Galkina E & Ley K (2007) Leukocyte influx in atherosclerosis. Curr Drug Targets 
8(12):1239-1248. 
273. Braunersreuther V, et al. (2008) A novel RANTES antagonist prevents progression of 
established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol 
28(6):1090-1096. 
274. Wong KL, et al. (2012) The three human monocyte subsets: implications for health 
and disease. Immunol Res 53(1-3):41-57. 
  68 
275. Wells JM, Gaggar A, & Blalock JE (2015) MMP generated matrikines. Matrix Biol 
44-46:122-129. 
276. Stansfield BK & Ingram DA (2015) Clinical significance of monocyte heterogeneity. 
Clin Transl Med 4:5. 
277. Appleby LJ, et al. (2013) Sources of heterogeneity in human monocyte subsets. 
Immunol Lett 152(1):32-41. 
278. Martyre MC, Beaupain R, & Falcoff E (1988) Human lung cancer nodules in 
organotypic culture: no evidence of correlation between the antiproliferative effects of 
interferons and the induction of 2',5'-oligoadenylate synthetase. Tumour Biol 
9(5):263-269. 
279. Oda D, et al. (1998) Reconstituted human oral and esophageal mucosa in culture. In 
Vitro Cell Dev Biol Anim 34(1):46-52. 
280. Tomakidi P, Fusenig NE, Kohl A, & Komposch G (1997) Histomorphological and 
biochemical differentiation capacity in organotypic co-cultures of primary gingival 
cells. J Periodontal Res 32(4):388-400. 
281. Andl CD, et al. (2016) Association of TGFbeta signaling with the maintenance of a 
quiescent stem cell niche in human oral mucosa. Histochem Cell Biol 146(5):539-555. 
282. Braian C, Svensson M, Brighenti S, Lerm M, & Parasa VR (2015) A 3D Human 
Lung Tissue Model for Functional Studies on Mycobacterium tuberculosis Infection. 
J Vis Exp (104). 
283. Buskermolen JK, et al. (2016) Development of a Full-Thickness Human Gingiva 
Equivalent Constructed from Immortalized Keratinocytes and Fibroblasts. Tissue Eng 
Part C Methods 22(8):781-791. 
284. Dalley AJ, AbdulMajeed AA, Upton Z, & Farah CS (2013) Organotypic culture of 
normal, dysplastic and squamous cell carcinoma-derived oral cell lines reveals loss of 
spatial regulation of CD44 and p75 NTR in malignancy. J Oral Pathol Med 42(1):37-
46. 
285. Kosten IJ, Buskermolen JK, Spiekstra SW, de Gruijl TD, & Gibbs S (2015) Gingiva 
Equivalents Secrete Negligible Amounts of Key Chemokines Involved in Langerhans 
Cell Migration Compared to Skin Equivalents. J Immunol Res 2015:627125. 
286. Rautava J, et al. (2012) Effects of tacrolimus on an organotypic raft-culture model 
mimicking oral mucosa. Clin Exp Dermatol 37(8):897-903. 
287. Hasturk H, Kantarci A, & Van Dyke TE (2012) Oral inflammatory diseases and 
systemic inflammation: role of the macrophage. Front Immunol 3:118. 
288. Lundegren N, Axtelius B, & Akerman S (2012) Oral health in the adult population of 
Skane, Sweden: a clinical study. Acta Odontol Scand 70(6):511-519. 
289. Dongari-Bagtzoglou A & Kashleva H (2006) Development of a highly reproducible 
three-dimensional organotypic model of the oral mucosa. Nat Protoc 1(4):2012-2018. 
290. Dickson MA, et al. (2000) Human keratinocytes that express hTERT and also bypass 
a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain 
normal growth and differentiation characteristics. Mol Cell Biol 20(4):1436-1447. 
   69 
291. Holland PM, Abramson RD, Watson R, & Gelfand DH (1991) Detection of specific 
polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of 
Thermus aquaticus DNA polymerase. Proc Natl Acad Sci U S A 88(16):7276-7280. 
292. Bao K, Papadimitropoulos A, Akgul B, Belibasakis GN, & Bostanci N (2015) 
Establishment of an oral infection model resembling the periodontal pocket in a 
perfusion bioreactor system. Virulence 6(3):265-273. 
293. Engering A, et al. (2002) The dendritic cell-specific adhesion receptor DC-SIGN 
internalizes antigen for presentation to T cells. J Immunol 168(5):2118-2126. 
294. Porcelli SA & Modlin RL (1999) The CD1 system: antigen-presenting molecules for 
T cell recognition of lipids and glycolipids. Annu Rev Immunol 17:297-329. 
295. Bechetoille N, et al. (2011) A new organotypic model containing dermal-type 
macrophages. Exp Dermatol 20(12):1035-1037. 
296. Spottl T, et al. (2006) A new organotypic model to study cell interactions in the 
intestinal mucosa. Eur J Gastroenterol Hepatol 18(8):901-909. 
297. Crabbe A, et al. (2011) Alveolar epithelium protects macrophages from quorum 
sensing-induced cytotoxicity in a three-dimensional co-culture model. Cell Microbiol 
13(3):469-481. 
298. Krutzik SR, et al. (2005) TLR activation triggers the rapid differentiation of 
monocytes into macrophages and dendritic cells. Nat Med 11(6):653-660. 
299. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, & Muller WA (1999) 
Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. 
Immunity 11(6):753-761. 
300. Cheong C, et al. (2010) Microbial stimulation fully differentiates monocytes to DC-
SIGN/CD209(+) dendritic cells for immune T cell areas. Cell 143(3):416-429. 
301. Linde N, Gutschalk CM, Hoffmann C, Yilmaz D, & Mueller MM (2012) Integrating 
macrophages into organotypic co-cultures: a 3D in vitro model to study tumor-
associated macrophages. PLoS One 7(7):e40058. 
302. Bernasconi E, et al. (2016) Airway Microbiota Determines Innate Cell Inflammatory 
or Tissue Remodeling Profiles in Lung Transplantation. Am J Respir Crit Care Med 
194(10):1252-1263. 
303. Morin MP & Grenier D (2017) Regulation of matrix metalloproteinase secretion by 
green tea catechins in a three-dimensional co-culture model of macrophages and 
gingival fibroblasts. Arch Oral Biol 75:89-99. 
304. Lenzo JC, et al. (2012) Control of macrophage lineage populations by CSF-1 receptor 
and GM-CSF in homeostasis and inflammation. Immunol Cell Biol 90(4):429-440. 
305. Greter M, et al. (2012) Stroma-derived interleukin-34 controls the development and 
maintenance of langerhans cells and the maintenance of microglia. Immunity 
37(6):1050-1060. 
306. Davanian H, et al. (2012) Gene expression profiles in paired gingival biopsies from 
periodontitis-affected and healthy tissues revealed by massively parallel sequencing. 
PLoS One 7(9):e46440. 
307. Demmer RT, et al. (2008) Transcriptomes in healthy and diseased gingival tissues. J 
Periodontol 79(11):2112-2124. 
  70 
308. Kebschull M, et al. (2014) Gingival tissue transcriptomes identify distinct 
periodontitis phenotypes. J Dent Res 93(5):459-468. 
309. Sorsa T, et al. (2016) Analysis of matrix metalloproteinases, especially MMP-8, in 
gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. 
Periodontol 2000 70(1):142-163. 
310. Rosa N, et al. (2014) The landscape of protein biomarkers proposed for periodontal 
disease: markers with functional meaning. Biomed Res Int 2014:569632. 
311. Goncalves PF, et al. (2013) Periodontal treatment reduces matrix metalloproteinase 
levels in localized aggressive periodontitis. J Periodontol 84(12):1801-1808. 
312. Churg A, et al. (2003) Macrophage metalloelastase mediates acute cigarette smoke-
induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care 
Med 167(8):1083-1089. 
313. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, & Shapiro SD (1996) 
Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion 
in mice. Proc Natl Acad Sci U S A 93(9):3942-3946. 
314. Narimiya T, et al. (2017) Orthodontic tensile strain induces angiogenesis via type IV 
collagen degradation by matrix metalloproteinase-12. J Periodontal Res 52(5):842-
852. 
315. Lanone S, et al. (2002) Overlapping and enzyme-specific contributions of matrix 
metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin 
Invest 110(4):463-474. 
316. Le Quement C, Guenon I, Gillon JY, Lagente V, & Boichot E (2008) MMP-12 
induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial 
cells. Am J Physiol Lung Cell Mol Physiol 294(6):L1076-1084. 
317. Hou P, et al. (2004) Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new 
lesson on the involvement of MMPs in bone resorption. Bone 34(1):37-47. 
318. Leppilahti JM, et al. (2014) Matrix metalloproteinases and myeloperoxidase in 
gingival crevicular fluid provide site-specific diagnostic value for chronic 
periodontitis. J Clin Periodontol 41(4):348-356. 
319. Lira-Junior R, Ozturk VO, Emingil G, Bostanci N, & Bostrom EA (2017) Salivary 
and Serum Markers Related to Innate Immunity in Generalized Aggressive 
Periodontitis. J Periodontol:1-13. 
320. Rathnayake N, et al. (2013) Salivary biomarkers of oral health: a cross-sectional 
study. J Clin Periodontol 40(2):140-147. 
321. Sapna G, Gokul S, & Bagri-Manjrekar K (2014) Matrix metalloproteinases and 
periodontal diseases. Oral Dis 20(6):538-550. 
322. Di Benedetto A, Gigante I, Colucci S, & Grano M (2013) Periodontal disease: linking 
the primary inflammation to bone loss. Clin Dev Immunol 2013:503754. 
323. Thiesen S, et al. (2014) CD14(hi)HLA-DR(dim) macrophages, with a resemblance to 
classical blood monocytes, dominate inflamed mucosa in Crohn's disease. J Leukoc 
Biol 95(3):531-541. 
   71 
324. Pilling D, Fan T, Huang D, Kaul B, & Gomer RH (2009) Identification of markers 
that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and 
fibroblasts. PLoS One 4(10):e7475. 
325. Al-Sharea A, et al. (2016) Native LDL promotes differentiation of human monocytes 
to macrophages with an inflammatory phenotype. Thromb Haemost 115(4):762-772. 
326. Gao S, Hao B, Yang XF, & Chen WQ (2014) Decreased CD200R expression on 
monocyte-derived macrophages correlates with Th17/Treg imbalance and disease 
activity in rheumatoid arthritis patients. Inflamm Res 63(6):441-450. 
327. Gu Y, Lee HM, Sorsa T, Simon SR, & Golub LM (2010) Doxycycline [corrected] 
inhibits mononuclear cell-mediated connective tissue breakdown. FEMS Immunol 
Med Microbiol 58(2):218-225. 
328. Kalinski P (2012) Regulation of immune responses by prostaglandin E2. J Immunol 
188(1):21-28. 
329. Legler DF, Bruckner M, Uetz-von Allmen E, & Krause P (2010) Prostaglandin E2 at 
new glance: novel insights in functional diversity offer therapeutic chances. Int J 
Biochem Cell Biol 42(2):198-201. 
330. Steenport M, et al. (2009) Matrix metalloproteinase (MMP)-1 and MMP-3 induce 
macrophage MMP-9: evidence for the role of TNF-alpha and cyclooxygenase-2. J 
Immunol 183(12):8119-8127. 
331. Lin Y, Cui M, Xu T, Yu W, & Zhang L (2014) Silencing of cyclooxygenase-2 
inhibits the growth, invasion and migration of ovarian cancer cells. Mol Med Rep 
9(6):2499-2504. 
332. Sanchez GA, Miozza VA, Delgado A, & Busch L (2013) Salivary IL-1beta and PGE2 
as biomarkers of periodontal status, before and after periodontal treatment. J Clin 
Periodontol 40(12):1112-1117. 
333. Matsumoto C, et al. (2012) Toll-like receptor 2 heterodimers, TLR2/6 and TLR2/1 
induce prostaglandin E production by osteoblasts, osteoclast formation and 
inflammatory periodontitis. Biochem Biophys Res Commun 428(1):110-115. 
334. Sun Y, Guo QM, Liu DL, Zhang MZ, & Shu R (2010) In vivo expression of Toll-like 
receptor 2, Toll-like receptor 4, CSF2 and LY64 in Chinese chronic periodontitis 
patients. Oral Dis 16(4):343-350. 
335. Wu L, Fan J, Matsumoto S-i, & Watanabe T (2000) Induction and Regulation of 
Matrix Metalloproteinase-12 by Cytokines and CD40 Signaling in 
Monocyte/Macrophages. Biochem Biophys Res Commun 269(3):808-815. 
336. van Nieuwenhuijze AE, et al. (2015) Complementary action of granulocyte 
macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, 
receptor activator of nuclear factor-kappaB ligand, and matrix metalloproteinases and 
drives bone and cartilage pathology in experimental arthritis: rationale for 
combination therapy in rheumatoid arthritis. Arthritis Res Ther 17:163. 
337. Gutschalk CM, et al. (2013) GM-CSF enhances tumor invasion by elevated MMP-2, 
-9, and -26 expression. Cancer Med 2(2):117-129. 
338. Hoek RM, et al. (2000) Down-regulation of the macrophage lineage through 
interaction with OX2 (CD200). Science 290(5497):1768-1771. 
  72 
339. Jiang L, et al. (2016) CD200Fc reduces TLR4-mediated inflammatory responses in 
LPS-induced rat primary microglial cells via inhibition of the NF-kappaB pathway. 
Inflamm Res 65(7):521-532. 
340. Mihrshahi R, Barclay AN, & Brown MH (2009) Essential roles for Dok2 and 
RasGAP in CD200 receptor-mediated regulation of human myeloid cells. J Immunol 
183(8):4879-4886. 
341. Zhang S, Cherwinski H, Sedgwick JD, & Phillips JH (2004) Molecular mechanisms 
of CD200 inhibition of mast cell activation. J Immunol 173(11):6786-6793. 
342. Xie S, et al. (2005) Induction and regulation of matrix metalloproteinase-12 in human 
airway smooth muscle cells. Respir Res 6:148. 
343. Itoh T, et al. (1996) Granulocyte-macrophage colony-stimulating factor provokes 
RAS activation and transcription of c-fos through different modes of signaling. J Biol 
Chem 271(13):7587-7592. 
344. Suzuki A, et al. (2004) Large-scale investigation of genomic markers for severe 
periodontitis. Odontology 92(1):43-47. 
345. Zhang Y, et al. (2016) The emerging landscape of salivary diagnostics. Periodontol 
2000 70(1):38-52. 
346. Trindade F, et al. (2014) Uncovering the molecular networks in periodontitis. 
Proteomics Clin Appl 8(9-10):748-761. 
347. van den Bosch MH, et al. (2016) Alarmin S100A9 Induces Proinflammatory and 
Catabolic Effects Predominantly in the M1 Macrophages of Human Osteoarthritic 
Synovium. J Rheumatol 43(10):1874-1884. 
348. Sunahori K, et al. (2006) The S100A8/A9 heterodimer amplifies proinflammatory 
cytokine production by macrophages via activation of nuclear factor kappa B and p38 
mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 8(3):R69. 
349. Foell D, Wittkowski H, Vogl T, & Roth J (2007) S100 proteins expressed in 
phagocytes: a novel group of damage-associated molecular pattern molecules. J 
Leukoc Biol 81(1):28-37. 
350. Oliveira da Silva C, et al. (2017) Time Course of the Phenotype of Blood and Bone 
Marrow Monocytes and Macrophages in the Lung after Cigarette Smoke Exposure In 
Vivo. Int J Mol Sci 18(9). 
351. Apatzidou DA, Riggio MP, & Kinane DF (2005) Impact of smoking on the clinical, 
microbiological and immunological parameters of adult patients with periodontitis. J 
Clin Periodontol 32(9):973-983. 
352. Pradeep AR, et al. (2014) Correlation of human S100A12 (EN-RAGE) and high-
sensitivity C-reactive protein as gingival crevicular fluid and serum markers of 
inflammation in chronic periodontitis and type 2 diabetes. Inflamm Res 63(4):317-
323. 
353. Jaedicke KM, Preshaw PM, & Taylor JJ (2016) Salivary cytokines as biomarkers of 
periodontal diseases. Periodontol 2000 70(1):164-183. 
354. Ramseier CA, et al. (2009) Identification of pathogen and host-response markers 
correlated with periodontal disease. J Periodontol 80(3):436-446. 
   73 
355. Haririan H, et al. (2016) Comparative Analysis of Calcium-Binding Myeloid-Related 
Protein-8/14 in Saliva and Serum of Patients With Periodontitis and Healthy 
Individuals. J Periodontol 87(2):184-192. 
356. Haigh BJ, et al. (2010) Alterations in the salivary proteome associated with 
periodontitis. J Clin Periodontol 37(3):241-247. 
357. Kwon CH, Moon HJ, Park HJ, Choi JH, & Park DY (2013) S100A8 and S100A9 
promotes invasion and migration through p38 mitogen-activated protein kinase-
dependent NF-kappaB activation in gastric cancer cells. Mol Cells 35(3):226-234. 
358. Nordal HH, et al. (2016) Calprotectin (S100A8/A9) and S100A12 are associated with 
measures of disease activity in a longitudinal study of patients with rheumatoid 
arthritis treated with infliximab. Scand J Rheumatol 45(4):274-281. 
359. Cremers NAJ, et al. (2017) S100A8/A9 increases the mobilization of pro-
inflammatory Ly6Chigh monocytes to the synovium during experimental 
osteoarthritis. Arthritis Res Ther 19(1):217. 
360. de Lima CL, et al. (2016) Host-derived salivary biomarkers in diagnosing periodontal 
disease: systematic review and meta-analysis. J Clin Periodontol 43(6):492-502. 
361. Gupta M, Chaturvedi R, & Jain A (2013) Role of monocyte chemoattractant protein-1 
(MCP-1) as an immune-diagnostic biomarker in the pathogenesis of chronic 
periodontal disease. Cytokine 61(3):892-897. 
362. Lira-Junior R, Akerman S, Gustafsson A, Klinge B, & Bostrom EA (2017) Colony 
stimulating factor-1 in saliva in relation to age, smoking, and oral and systemic 
diseases. Sci Rep 7(1):7280. 
363. Bostanci N, Ozturk VO, Emingil G, & Belibasakis GN (2013) Elevated oral and 
systemic levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-
1) in periodontitis. J Dent Res 92(2):161-165. 
364. Ebersole JL, et al. (2013) Patterns of salivary analytes provide diagnostic capacity for 
distinguishing chronic adult periodontitis from health. J Clin Immunol 33(1):271-279. 
365. Kinney JS, et al. (2011) Saliva/pathogen biomarker signatures and periodontal disease 
progression. J Dent Res 90(6):752-758. 
366. Korte DL & Kinney J (2016) Personalized medicine: an update of salivary 
biomarkers for periodontal diseases. Periodontol 2000 70(1):26-37. 
367. Mitani A, et al. (2015) Increased expression of interleukin (IL)-35 and IL-17, but not 
IL-27, in gingival tissues with chronic periodontitis. J Periodontol 86(2):301-309. 
368. Castro ML, et al. (2016) Downregulation of Proteinase-Activated Receptor-2, 
Interleukin-17, and Other Proinflammatory Genes by Subantimicrobial Doxycycline 
Dose in a Rat Periodontitis Model. J Periodontol 87(2):203-210. 
369. Kirkham BW, Kavanaugh A, & Reich K (2014) Interleukin-17A: a unique pathway in 
immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. 
Immunology 141(2):133-142. 
370. Abusleme L & Moutsopoulos NM (2017) IL-17: overview and role in oral immunity 
and microbiome. Oral Dis 23(7):854-865. 
371. Cua DJ & Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune 
system. Nat Rev Immunol 10(7):479-489. 
  74 
372. Morimoto A, et al. (2017) Inflammatory serum cytokines and chemokines increase 
associated with the disease extent in pediatric Langerhans cell histiocytosis. Cytokine 
97:73-79. 
373. Chen XT, Tan JY, Lei LH, & Chen LL (2015) Cytokine levels in plasma and gingival 
crevicular fluid in chronic periodontitis. Am J Dent 28(1):9-12. 
374. Kvedaraite E, et al. (2016) Tissue-infiltrating neutrophils represent the main source of 
IL-23 in the colon of patients with IBD. Gut 65(10):1632-1641. 
375. Brereton CF, Sutton CE, Lalor SJ, Lavelle EC, & Mills KH (2009) Inhibition of ERK 
MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates 
autoimmune disease. J Immunol 183(3):1715-1723. 
376. Chakraborty R, et al. (2016) Alternative genetic mechanisms of BRAF activation in 
Langerhans cell histiocytosis. Blood 128(21):2533-2537. 
 
 
